Document:

Exhibit 10.35

 

CONFIDENTIAL

 

EXCLUSIVE DISTRIBUTION AGREEMENT

 

THIS
EXCLUSIVE DISTRIBUTION AGREEMENT (“Agreement”) is made and entered into effective as of the date the last party hereto
signs as shown on the signature page (“Effective Date”), and Is by and between Aurastem Technologies, LLC., a Delaware
company having its primary office and place of business at 420 Stevens Avenue, Suite 220, Solana Beach, CA 92075 and any of its
Affiliates who now hold or hereafter will hold any rights related to these Products with in the Territory in Field of Use
(“Aurastem”), and Suneva Medical, Inc., a Delaware corporation having Its primary office and place of business at 5870
Pacific Center Blvd, San Diego, CA 92121(“Distributor”).

 

RECITALS:

 

WHEREAS, Aurastem
desires to have Distributor develop a demand for, and to act as Its exclusive distributor for, the Products (as defined herein) within
the Territory and Field of Use; and

 

WHEREAS, Distributor
desires to be designated as the exclusive distributor of Products within the Territory and Field of Use land to maintain the expertise,
staff, resources and other necessary investments to carry out the terms of this Agreement.

 

NOW, THEREFORE,
In consideration of the foregoing recitals and the mutual covenants contained herein, Aurastem and Distributor hereby agree .as follows:

 

		1.	Certain Definitions. As used In this Agreement, the
terms set forth below shall have the following meanings:

 

		1.1	“Products” shall mean Products listed in Schedule 1.1

 

		1.2	“Territory”/“Territories” shall mean the United States of America and Canada.

 

		1.3	“Field of Use” shall mean the medical aesthetics field,
including but not limited to the field of autologous fat transplantation.

 

		1.4	“Customers” shall mean physicians, med-spas, clinics,
and other end-users or potential end-users of the Products, as well as other sub-distributors within the Field of Use to whom Distributor
may sell Products. For avoidance of doubt, “Customers” does not Include patients who will buy and be treated with the Products.

 

		1.5	“Affiliate” shall mean, with respect to any Person,
any other Person which directly or indirectly controls,.Is controlled by, or Is under common control with, such Person, only for so long
as such control continue to exist. A Person shall be regarded as in control of another Person If it owns, or directly or indirectly controls,
at least fifty percent (50%) of the voting stock or other ownership interest of the other Person, or if It directly or. indirectly possesses
the power to direct or cause the direction of the management and policies of the other Person by any means whatsoever.

 

		1.6	“Person” means an Individual, corporation, partnership,
limited liability company, trust, business trust, association, joint venture, non-profit organization, pool, syndicate, sole proprietorship,
unincorporated organization, university, governmental authority or any other form of entity not specifically listed herein.

 

    
	(Initials)
	 1 of 11	 

 

     

    

 

		2.	Grant of Exclusive Distribution Rights.

 

		2.1	Appointment. Upon
                                            the terms and subject to the conditions contained herein, Aurastem hereby appoints Distributor
                                            its exclusive Distributor of the Products within the Territory, Field of Use. Such grant
                                            Is expressly contingent upon Distributor maintaining compliance with minimum purchase requirements
                                            specified In Schedule 1.2.

 

		2.2	Acceptance of Exclusive
                                            Appointment. Distributor hereby accepts the grant of exclusive distribution rights specified
                                            In Section 2,1 appointment as Aurastem’s exclusive distributor of Products In the Territory
                                            for the designated Field of Use and agrees fully and faithfully to perform and discharge
                                            all of Its duties, obligations and responsibilities, and to abide by the restrictions set
                                            forth in this Agreement.

 

		2.3	Independent Contractors.
                                            The relationship of Aurastem and Distributor established by this Agreement is that of Independent
                                            contractors, and nothing contained In this Agreement shall be construed to give either party
                                            hereto any control over, or power or authority as agent; employee,, partner, creditor, shareholder,
                                            or In any other capacity to represent, act for, bind or otherwise create or assume an obligation
                                            on behalf of the other for any purpose whatsoever.

 

		2.4	Duties, Obligations and Restrictions of Distributor.
Distributor agrees to use commercially reasonable efforts to develop the full sales potential of the Territory for the Field of Use,
Including the following duties:

 

		(a)	Distributor shall introduce and diligently promote, sell and service the Products within the Territory
and Field of Use. Distributor will, In good faith, consider for dissemination to its customers all promotional materials supplied by Aurastem.
Aurastem will provide Distributor with a commercially reasonable number of Non-sellable free goods/samples as specified in Schedule
1.2, for promotional activities.

 

		(b)	Aurastem shall provide to Distributor, at Aurastem’s own expense, training related to the ‘use and. maintenance
of the Products, and customer service training related to Product ordering and fulfillment. Following such training by Aurastem, Distributor
will be responsible for training Customers In the Territory In appropriate use and maintenance of the Products.’

 

		(c)	Distributor will be responsible for all Customer service activities within the Territory, including receipt
and fulfillment of orders from, shipping to; and handling of Product returns from, Customers, All revenues In the Territory will be recorded
by Distributor, and Distributor has the right to collect funds and report the corresponding revenue (to the extent appropriate under applicable
accounting rules) to third parties.

 

		(d)	Distributor will direct any warranty related issues outside the scope of Distributor’s responsibilities
to Aurastem.

 

		(e)	Distributor may organize, at its own expense; any dinners or symposia associated with medical education
activities In connection with promotion of the Products. For clarity, such dinners or activities may be held outside the Territory, provided
that invitees are solely Customers within the Territory. In the event Distributor organizes such activities, It shall be responsible for
all associated expenses, Including for example, room or booth rentals at promotional events, and printing costs of any new marketing communication
materials.

 

		(f)	Distributor shall not (A) seek Customers or establish any branch or maintain any distribution depot for the Products In any country that
Is outside the Territory; or (B) sell the Products
to any Customer in any country that is (I) outside the Territory or (ii) within the Territory If to the knowledge of the Distributor that
Customer intends to resell the Products in any country that is outside the Territory. Aurastem will not and will not knowingly permit
or allow others to (A) sell the Products to any customer In any country that is (i) inside the Territory or (ii) outside the Territory
If to the knowledge of Aurastem, that Customer Intends to resell the Products in any country that is Inside the Territory.

 

    
	(Initials)
	 2 of 11	 

 

     

    

 

		(g)	Distributor shall refer to Aurastem for direct action any orders or Inquiries for Products from customers
outside of the Territory or which involve nonstandard versions of the Products.

 

		(h)	Distributor will implement
promotional and merchandising efforts for the Products. Distributor shall provide to Aurastem at
least one (1) copy of all of Distributor’s advertising and sales promotion materials in which any
Products are mentioned, and at least one (1) copy of any translations of any manuals or other materials provided to Distributor by Aurastem (collectively the “Documentation”), Distributor shall not use any such Documentation until Aurastem has approved such use in writing, which approval will be provided to Distributor not later than ten (10) business days following Distributor’s submission to Aurastem. Aurastem may reject and Distributor shall not make use of any such Documentation that Aurastem, in its sole discretion, deems undesirable.

 

		(I)	Distributor will comply with all applicable state and local laws and regulations, and will not knowingly
assist or participate In any violation of laws or regulations applicable to Aurastem or Distributor, including but not limited to the
Food Drug and Cosmetic Act and regulations promulgated thereunder and export controls and similar regulations (such as the Export
Administration Regulations of the U.S. Department of Commerce (the “EAR”),
which may restrict or require licenses for the export of Products from the United States and their re-export from other countries,

 

		(j)	Distributor shall make no false or misleading representations to Customers or other Persons with regard
to the Products or Aurastem, and shall not make any representations with respect to the specifications, features or capabilities of the
Products which are not consistent with those described In literature distributed by Aurastem.

 

		(k)	Distributor agrees to provide Aurastem Customer information for the Products on a monthly basis. The Customer
list shall Include name, address, total annual products purchased by Customer, and annual revenue generated by Customer. Distributor will
comply with the Minimum Customer end user Pricing Floors specified In Schedule 1.3 during the Term.

 

		(I)	During the Term of this Agreement, neither Distributor nor any of its Affiliates will market, sell, or
develop any competing form of autologous adipose tissue processing product. For avoidance of doubt, this prohibition does not apply to
politely rich plasma (PRP), platelet rich plasma (PRF), or allogeneic adipose tissue Injectable product.

 

		(m)	Aurastem Is entitled to visit all Customers and maintain
a relationship with such Customers and reserves the right to sell Customers products in the Territory other than the Products sold by
Distributor.

 

    
	(Initials)
	 3 of 11	 

 

     

    

 

		3.	Purchases and Sales of Products.

 

		3.1	Initial Order. Upon US FDA Clearance of one or more
of the Products, Distributor will deliver to the Aurastem a pre-paid product order in the amount of three thousand (3000) units. The
Initial Order amount of three thousand .units will be applied to the Year 1, Quarter 1 Minimum Product Purchase Requirements as specified
in Schedule 1.2.

 

		3.2	Forecasts/Commitment
                                            to Minimum Quarterly Purchase Requirements. Following the Initial Order, purchase orders
                                            will be placed by Distributor on a quarterly basis. Such orders will be at least of the quantity
                                            specified In the Minimum Product Purchase Requirement for. a given Quarter according to Schedule
                                            1.2. The Minimum Product Purchase Requirement obligations and associated obligations
                                            to place purchase orders shall be suspended and of no effect for any period of time during
                                            which a Product has been withdrawn from the market or is the subject of a hold or recall
                                            or similar circumstance that prevents or significantly Impairs the ability of Distributor
                                            to sell the Products. Moreover, during Year 1 and only Year 1, purchases In excess of any
                                            Quarter’s Minimum Product Purchase Requirement shall be allowed to “roll over”
                                            into the subsequent Quarter and count as part of the subsequent Quarter’s Minimum Product
                                            Purchase Requirement.

 

		3.3	Ordering Procedure. The following shall apply to all
orders placed hereunder:

 

		(a)	Purchases and sales of the Products between Distributor and Aurastem under this Agreement shall be made
by means of purchase orders submitted by Distributor to Aurastem, specifying, among other things, the number of units and unit price of
each Product ordered under each purchase order, and the desired date and place of delivery. In the event of termination of this Agreement
per Section 15, Distributor shall have the right to cancel any outstanding quantity remaining on any purchase order then in place
with Aurastem. The terms and provisions of this Agreement shall govern and control each purchase order submitted by Distributor to Aurastem,
and any conflicting provisions contained In any such purchase order shall have no force and effect whatsoever.

 

		(b)	Aurastem will accept any order that is provided by Distributor In compliance with this Agreement.
                                                             Aurastem reserves the right to reject or modify the delivery terms of any order without In any way affecting the obligations of
                                                             either party under this Agreement; provided, that Aurastem gives Distributor, In a timely fashion and in writing, a reasonable
                                                             Justification for the rejection or modification of any order, and an estimated delivery date for any orders where the requested
                                                             delivery date was changed. For clarity, so long as Distributor places an order for such amounts as required by Section 3.2,
                                                             Distributor will have met its obligations under Section 3.2, regardless of whether Aurastem subsequently rejects or modifies
                                                             such order.

 

		(c)	Aurastem reserves the right to reject or modify the delivery terms of any order without in any way affecting
the obligations of either party under this Agreement; provided, that Aurastem gives Distributor, in a timely fashion and In writing, a
reasonable Justification for the rejection of any order, and an estimated delivery date for any orders where the requested delivery date
was changed.

 

		3.4	Product Packaging. The parties will collaborate to develop packaging for the Territory, which
                                                                               may, at Distributor’s option, include brand marks and logos of Distributor. Aurastem agrees to cause the Products to be packed
                                                                               pursuant to Its standard export procedure (and applicable specifications, laws, and regulations) and to deliver the Products to
                                                                               Distributor in accordance with the terms of each purchase order as accepted by Aurastem (to the extent consistent with this
                                                                               Agreement). The above notwithstanding, It is the obligation of the Distributor to ensure compliance with local regulations on this
                                                                               and other requirements In the Territory as set forth in section 6.

 

    
	(Initials)
	 4 of 11	 

 

     

    

 

		3.5	Title, Acceptance, Risk of Loss and Returns. Title
to Products and all risk of loss shall pass from Aurastem to Distributor at the time and place of Aurastem’s delivery of Products to
Distributor, FCA (incoterms 2010) Shipping Point. Distributor shall be solely responsible for Insuring Products after delivery to the
Distributor, FCA Shipping Point. Products may be returned only as provided by any specific warranties of Aurastem pursuant to this Agreement.

 

		3.6	Foreign
                                            Corrupt Practices Act. Distributor and Aurastem each represent and warrant that It will
                                            comply with all laws applicable In the Territory relating to. the conduct of business practices,
                                            including those that may prohibit gratuities, Inducements, or certain other payments; including,
                                            payments of money or anything of value offered, promised or paid, directly or indirectly,
                                            to any government official, or public or political officer, to Induce such official to use
                                            their Influence with a government or instrumentality to obtain an Improper business advantage
                                            for the Aurastem or Distributor In relation to this Agreement. Distributor and Aurastem acknowledge
                                            that each may be subject to certain United States laws, Including the Foreign Corrupt Practices
                                            Act of 1977 and any of its amendments, which. may apply to activities carried out on Aurastem’s
                                            or Distributor’s behalf outside the United States of America.. Distributor and Aurastem
                                            each agrees neither to take nor omit to take any action If such act or omission might cause
                                            Aurastem or Distributor to be in violation of any such .laws. Upon written Notice from Aurastem
                                            or Distributor, as the case may be, the other party shall provide such Information as Aurastem
                                            or Distributor may reasonably consider. necessary to verify compliance by Aurastem or Distributor
                                            with the provisions of this Section.

 

		4.	Product Prices. Distributor’s purchase price for the
Products are set forth on Schedule 1.1 (Products
and Price List), as issued and changed by Aurastem from time to time on at least thirty (30) days
Notice.

 

		5.	Payment for Products.

 

		5.1	Payment Terms. All orders shall be pre-paid by distributor.

 

		6,	 Regulatory Matters. Aurastem will use commercially
reasonable efforts to maintain any regulatory approvals of any Products In the Territory that exist as of the date of this Agreement.
Aurastem will allow Distributor to access- and to reproduce, for purposes of regulatory filings and correspondence in the Territory,
any regulatory filings, supportive data, and regulatory correspondence (“Regulatory Materials”) developed or otherwise possessed
by Aurastem, and will promptly disclose any new Regulatory Materials to Distributor. Aurastem shall be responsible for maintaining any
regulatory approvals for sale currently applicable in the Territory, and will cooperate with any information or other requests that regulatory
authorities may convey, either to Distributor or Aurastem. For countries In which Aurastem Is unable or unwilling to obtain approval,
Distributor may attempt to obtain approval at distributors sole expense, and Aurastem Will cooperate with such Distributor efforts.

 

Aurastem agrees
that its factory, facilities, operations and quality systems (or those of any third party} used to make Products may be inspected and/or
audited by Distributor at reasonable Intervals, provided that Distributor gives at least thirty (30) days Notice to Aurastem of its desire
to undertake such an Inspection and/or audit. Aurastem will also provide Distributor with Notice of any third-party quality and/or manufacturing
audits to be performed by regulatory authorities and notified bodies.

 

Distributor
shall be responsible for complying with any and all applicable statutory, administrative or regulatory requirements of the Territory
for Product labeling and packaging, product documentation such as traceability, samples, sales literature and records, and
documentation for recalls, Including but not limited to product serial numbers for each product sold identifiable by account and
date of sale, which documentation shall be maintained for durations as required by regulations In each country in the Territory by
the Distributor, notwithstanding termination or expiration of this Agreement. Distributor shall also assist Aurastem In the
Implementation of any Product recalls at Aurastem’s expense.

 

    
	(Initials)
	 5 of 11	 

 

     

    

 

		7.	Confidential Information.

 

		7.1	Definition. Each of the parties hereto recognizes
that the relationship created by this Agreement may involve access by Distributor and Aurastem to information of substantial value to
the other party, including, but not limited to, designs, drawings, plans, devices, trade secrets, clinical data, applications, formulae,
know-how, methods, techniques, and processes (whether related to the Products, or otherwise), as well as financial, business, marketing
and product development information, and customer lists relating to the Products (collectively,

“Confidential
Information”), provided that Confidential Information shall not Include Information, only In
so far as such Information Is: (a) In the public domain or which subsequently falls Into the public domain, (b) specifically
Intended by Aurastem for disclosure to Customers of Distributor, (c) information which the non-disclosing party can prove was
already known to It prior to the date of this Agreement, or (d) disclosed to the non-disclosing party in good faith by a third party
having a legal right to do so.

 

		7.2	Non-Disclosure. Each of the parties hereto acknowledges and agrees that the Disclosing party
                                                                                                                    owns all right, title and interest in and to such party’s Confidential Information. Each of the parties hereto further agrees
                                                                                                                    that It shall (a) maintain the secrecy and confidentiality of all Confidential Information which comes to its attention, (b) take
                                                                                                                    all necessary precautions to prevent any disclosure of confidential Information by any person within such party having access to
                                                                                                                    said Confidential information, and (c) during the Term of this Agreement and for so long as Confidential Information does not enter
                                                                                                                    into the public domain through an act or omission of either party, neither publish, disclose nor disseminate any part of such
                                                                                                                    Confidential Information in any manner, or use the same, without the prior written consent of the. disclosing party. Each party
                                                                                                                    recognizes and agrees that the non disclosing party may disclose Confidential Information of the Disclosing party to the extent (and
                                                                                                                    only to the degree) that it is required to do so by applicable laws and governmental regulations. Disclosing party shall be notified
                                                                                                                    at the earliest opportunity prior to any disclosure required by law or governmental authority. 

 

		7.3	Injunctive Relief. Each of the parties hereto understands and agrees that the Confidential
                                                                               Information has special value, the loss of which cannot be reasonably or adequately compensated In damages or in an action at law,
                                                                               and therefore, In the event of any breach or violation of the provisions of this Section 7 by Aurastem or Distributor, the
                                                                               non-breaching party shall be entitled to equitable relief by way of Injunction without the necessity of proving actual
                                                                               damages, which relief shall be in addition to, and not in limitation of, any other relief or rights to which such party may be
                                                                               entitled.

 

		7.4	Survival. The terms and provisions of this Section
7 shall survive any termination or expiration of this Agreement.

 

		8.	Warranty. The sole warranty given by Aurastem regarding any Product shall be that
written limited warranty provided In Schedule 1.4. as It may from time to time be amended by mutual written consent of Distributor
and Aurastem (the “Warranty”). Distributor agrees to provide to Its customers within the Territory a written warranty for each
particular Product on terms at least as favorable to Customers as that supplied by Aurastem for such Product. Excepting cases of gross
negligence, willful misconduct by Aurastem or In the case of third party personal injury claims based on a theory of product liability,
In no event Aurastem’s total liability for any claim or action
in connection with a Product exceed the purchase price of the Products out of which such claim or action
arose.

 

EXCEPT
AS EXPRESSLY SO WARRANTED, AURASTEM HEREBY DISCLAIMS ALL WARRANTIES, EXPRESS, STATUTORY AND IMPLIED, APPLICABLE TO THE PRODUCTS
INCLUDING, BUT NOT LIMITED TO, ANY WARRANTY OF MERCHANTABILITY, DESIGN, AND/OR FITNESS FOR A PARTICULAR PURPOSE,. THE WRITTEN
LIMITED WARRANTY, IF ANY, APPLICABLE TO ANY PARTICULAR PRODUCT SHALL STATE THE FULL EXTENT OF ‘AURASTEM’S LIABILITY,
WHETHER DIRECT OR INDIRECT, SPECIAL OR CONSEQUENTIAL, RESULTING FROM ANY BREACH OF SUCH WARRANTY, AURASTEM FURTHER DISCLAIMS ALL
EXPRESS, STATUTORY AND IMPLIED WARRANTIES APPLICABLE TO THE PRODUCTS WHICH ARE NOT MANUFACTURED BY AURASTEM, OR BY A LICENSEE OR
SUBLICENSEE OF AURASTEM, THE ONLY WARRANTIES APPLICABLE TO PRODUCTS NOT MANUFACTURED BY AURASTEM, OR BY A LICENSEE OR SUBLICENSEE
THEREOF SHALL BE THE WARRANTIES, IF ANY, OF THE MANUFACTURERS OF THOSE ITEMS.

 

    
	(Initials)
	 6 of 11	 

 

     

    

 

		9.	Trademarks.

 

		9.1	Aurastem Marks. Aurastem owns or has the right to use certain trademarks, service marks
                                                                               and/or trade names in connection with the sale of the Products (the “Aurastem Marks”), Including without
                                                                               limitation those trademarks, service marks and trade names used by Aurastem on or in conjunction with Products. Certain Aurastem
                                                                               Marks may be registered In the jurisdiction(s) which comprise the Territory.

 

		9.2	Use of Aurastem Marks by Distributor. Aurastem hereby grants to Distributor an exclusive
                                                                               right and license to use the specified Aurastem Marks solely In connection with the promotion, sale and distribution of the Products
                                                                               within the Territory and within the Field of Use. This right shall expire upon expiration or earlier termination of this Agreement.
                                                                               This right and license shall not be assignable or transferable by Distributor except by permitted assignment of this Agreement,
                                                                               provided, however, that Distributor may provide marketing materials containing the Aurastem Marks to sub-distributors for marketing
                                                                               purposes in the Territory. Distributor acknowledges that (a) Aurastem owns the Aurastem Marks and all goodwill associated with or
                                                                               symbolized by Aurastem Marks, (b) Distributor has no ownership right in or to any Aurastem Marks. Distributor shall use Aurastem
                                                                               Marks only in the form and manner prescribed from time to time by Aurastem, although for clarity Distributor will have discretion
                                                                               over use of Distributor’s own trademarks and trade dress in packaging and marketing materials within the Territory.
                                                                               Distributor shall submit to Aurastem for its written approval before any use Is made thereof, representative samples of all
                                                                               Products, stationery, Invoices, catalogs, brochures, packages, containers, and advertising or promotional materials bearing any of
                                                                               Aurastem Marks which Distributor or Its Agents prepare. Aurastem shall have the absolute right to approve or reject any proposed
                                                                               use of any of Aurastem Marks, in its sole discretion.

 

		9.3	Registration/Notice.
                                            Aurastem shall have the sole and exclusive right to obtain trademark registration worldwide
                                            for any Aurastem Marks or to take such other action with respect to the Aurastem Marks as
                                            it deems appropriate, and Distributor may not file registrations for any Aurastem Marks or
                                            any confusingly similar marks anywhere in the world. Distributor shall notify Aurastem promptly
                                            of any unauthorized use of Aurastem Marks or of any mark confusingly similar thereto which
                                            comes to its attention.

 

		10.	Patent Ownership and Rights to Inventions.

 

		10.1	No Ownership By Distributor.
Distributor shall not be deemed by anything contained In this Agreement or done pursuant to this Agreement to acquire any right, title
or Interest in or to any Aurastem Patents, trade secrets or technology, or any patent now or hereafter covering or applicable to any
Product, nor In or to any invention or Improvement now or hereafter embodied In any Product, whether or not such invention or improvement
Is patentable under the laws of any country.

 

		11.	Infringement of Third Party Rights.

 

		11.1	Warranty by Aurastem re Third Party Rights. Aurastem
represents and warrants that, to Its knowledge, the Products (including, without limitation any processes, techniques or know-how contained
therein, or utilized In the manufacture or use thereof) will not Infringe any Third Party Rights, Including Intellectual property rights.

 

		11.2	Notice and Defense. If any claim, action or Notice
is asserted against Aurastem or Distributor alleging that a Product infringes any Third-Party Rights, the party first notified shall
immediately notify the other party In writing of such claim, action or Notice brought against Aurastem or Distributor. Aurastem will
indemnify and hold Distributor harmless against and such claims and may, In its sole discretion, select counsel for, and control the
management, or defense with respect to any such claim, action or Notice, provided that Aurastem

 

    
	(Initials)
	 7 of 11	 

 

     

    

 

		11.3	Third Party Infringers.
                                            If Distributor becomes aware that a third party is or may be making unauthorized use of (a)
                                            any patent owned by Aurastem, or for which Aurastem has the exclusive right of use, which
                                            relates to the Products (“Aurastem’s Patents”), Distributor shall promptly give
                                            Aurastem written Notice thereof, which Notice shall fully describe the potentially Infringing
                                            action of such third party. Distributor shall consult with Aurastem with respect to any suit,
                                            Injunction, or other action taken against such third party, and will consider In good faith
                                            any Input provided by Aurastem. Distributor shall cooperate with Aurastem, at no out-of-pocket
                                            expense to Distributor, In connection with any action taken by Aurastem to terminate the
                                            Infringements, seek damages, or otherwise seek redress for the Infringement.

 

		12.	Claims.

 

		12.1	Notice from Distributor. Distributor shall promptly notify Aurastem of any potential or
                                                                                actual claim, litigation or governmental activity In the Territory relating to the Products or the business operations of
                                                                                Distributor or Aurastem(“Claims”). Distributor shall provide such Notice within seven business (7) days from the time
                                                                                that Distributor learns of such Claims.

 

		12.2	Indemnification by Distributor. Distributor assumes
sole responsibility for all acts performed by It pursuant to this Agreement and shall be solely responsible for all Claims In connection
therewith. Distributor shall Indemnify, defend and hold Aurastem harmless from any and all claims, actions, lawsuits, demands, costs,
liabilities, losses, damages and/or expenses (including reasonable attorneys’ fees and costs of litigation) by any other party resulting
from or relating to any acts, omissions or misrepresentations of Distributor, Its Agents or any of them.

 

		12.3	Indemnification
                                            by Aurastem. Aurastem assumes sole responsibility for all acts performed by it pursuant
                                            to this Agreement and shall be solely responsible. for all Claims in connection therewith.
                                            Aurastem shall indemnify, defend and hold Distributor harmless from any and all claims, actions,
                                            lawsuits, demands, costs, liabilities, losses, damages and/or expenses (including reasonable
                                            attorneys’ fees and costs of litigation) by any
                                            other party resulting from or relating to any acts, omissions or misrepresentations of Aurastem.

 

		12.4	Indemnifying party may control the defense of any claim for
which indemnification Is tendered, provided it promptly assumes such defense and selects counsel reasonably acceptable to the party to
be indemnified, and provided reasonable assurances with respect \o such defense can be provided. The Indemnified party shall cooperate
In the defense and shall have the right to consent to any settlement of the claims provided that such consent may not be withheld In
the event that the proposed settlement fully releases the indemnified party from all Claims.

 

		13.	Insurance.
To the extent commercially available, both Aurastem and Distributor shall maintain in full force and effect product liability insurance
and property damage insurance on its operations, with coverage limitations and terms of $300,000 per occurrence and $11000,000
total.

 

		14.	Term. The ,:erm of this Agreement shall be for a period of three (3) years commencing on the
                                                                                   Effective Date of this Agreement (the “Initial Term”), A single, two (2) year extension term will be granted automatically
                                                                                   to Distributor provided that: (I) the Minimum Product Purchase Requirements defined in Schedule 1.2 during the Initial Term
have been met or exceeded.

 

    
	(Initials)
	 8 of 11	 

 

     

    

 

		15.	Termination/Suspension of Performance.

 

		15.1	Suspension or Termination of a Party’s obligations may occur as follows:

 

		(a)	Aurastem, and only Aurastem, may terminate the Agreement In its entirety without cause, In its sole
                                                             and absolute discretion, with 180 days advance written notice to Distributor; 

 

	 	(b)	either party may terminate this Agreement If the other party breaches any of Its obligations In this Agreement, or Is in default of any term. or provision hereunder, which, if curable, is not cured within thirty (30) days of delivery of the written Notice of breach;

 

		(c)	either party may immediately terminate this Agreement by written notice In the event (I) an encumbrancer
takes possession or a receiver is appointed over any of the property or assets of the other party, (ii}
the other party makes any voluntary arrangement with Its creditors or becomes subject to an administration order, (Ill) the other party
goes Into liquidation (except for the purposes of amalgamation or reconstruction and In such manner that the company resulting therefrom
effectively agrees to be bound by or assume the obligations imposed on that other party under this Agreement), (iv) the other party becomes
the subject of anything that, under the law of any Jurisdiction, Is analogous to any of the acts or events specified in (i) - (iii)
of this Section 15(c), or (v) the other party ceases, or threatens to cease, to carry on business.

 

		15.2	At
the conclusion of this Agreement, by termination or otherwise, Distributor will provide Aurastem with a copy of all Customer accounts
and associated information In Distributor’s records, and all tangible and Intangible records regarding the distribution of Aurastem
Products (and Distributor may retain the same for Its Internal business purposes and regulatory and legal compliance purposes).

 

		15.3	Excusable Delays. Aurastem shall not be liable for any delay In the manufacture or delivery
                                                                                of Products pursuant to the terms and provisions of this Agreement, or for any damages suffered by Distributor by reason of such
                                                                                delay, when such delay Is, directly or .indirectly, caused by, or in any manner arises from, fires, floods, accidents, riots, acts
                                                                                of God, war, governmental Interference or restrictions, strikes, labor difficulties, back-orders, material shortages, regulatory or
                                                                                business interruptions, acts of Distributor or any other cause beyond the reasonable control of Aurastem, whether similar or
                                                                                dissimilar to the foregoing.

 

		16.	General Provisions.

 

		16.1	Successors and Assigns. Distributor shall not have
the right to assign any of Its rights, delegate any of its duties, or sub-rep or contract out any of its duties under this Agreement
without the prior written consent  of Aurastem, provided that Aurastem may not unreasonably withhold such consent.

 

		16.2	Notices. All Notices, requests, demands and other
communications which may be given or are required to be given under this Agreement shall be In writing and in the English language. All
Notices may be sent by facsimile transmission, or confirmed e-mail transmission provided they are confirmed by letter, or sent by certified
mall return receipt requested, and shall be deemed given oh the date of confirmed transmission or five (5) days after mailing via a reputable
carrier. All Notices shall be addressed as set forth below, or to such other address as each party hereto may from time to time designate
by written Notice to the other party as provided herein:

 

    
	(Initials)
	 9 of 11	 

 

     

    

 

To Distributor:

 

Suneva Medical, Inc. 

5870
Pacific Center Blvd.

San Dlego, CA 92121

 

Tel:

Email: m

Attention:

 

To Aurastem:

 

Aurastem Technologies, LLC

 420
Stevens Avenue, Suite 220

 Solana Beach, CA 92075

 

Tel:

Email: mailto:bconlan@puregraft.com

Attention:

 

		16.3	Governing Law. This Agreement has been. executed and delivered in, and shall be governed by
                                                                                                                                                and construed In accordance with the laws of the,State of California, United States of America applicable to contracts made and
                                                                                                                                                performed in such state and without regard to conflict of laws provisions. The Convention for the International Sale of Goods will
                                                                                                                                                not apply.

 

		16.4	Resolution
                                            of Disputes. in the event of any controversy or claim arising out of or relating to this
                                            Agreement, it shall be resolved through binding arbitration through the American Arbitration
                                            Association (the “AAA”)
                                            as provided herein. The parties hereto shall Notice the other part,y and the AAA,
                                            demand that the dispute be fully and finally settled by binding arbitration in accordance
                                            with the Rules and Procedures of the AAA In San Diego, California. The AAA shall appoint
                                            a single neutral arbitrator in accordance with their rules. The arbitration shall be conducted
                                            in English. Either party may seek interim Injunctive relief from the AAA through the application
                                            for a special master. Service of process In any such action or proceeding brought hereunder
                                            may be made by mailing copies of such process to the address of Notice to the. parties provided
                                            for in this Agreement.

 

		16.5	Headings.
                                            The headings herein are for convenience .only, do not constitute a part of this Agreement,
                                            and shall. not be deemed to limit or affect any of the terms or provisions hereof.

 

		16.6	Waiver
                                            and Amendment. No waiver, amendment, modification or change of any provision of this
                                            Agreement shall be effective unless and until made in writing and signed by all of the parties
                                            hereto or constitute a continuing waiver by such party of compliance with such provision
                                            unless so stated,

s

		16.7	Severability. The provisions of this Agreement are
intended to be interpreted and construed in a manner so as to make such provisions valid, binding and enforceable. In the event that
any provision of this Agreement Is determined to be partially or wholly Invalid, illegal or unenforceable, then such provision shall
be deemed to be modified or restricted to the extent necessary to make such provision valid, binding and enforceable.

 

		16.8	Counterparts. This Agreement may be executed in one
or more counterparts, each of which shall be deemed to be an original, but all of which together shall constitute one and the same
instrument.

 

		16.9	Entire Agreement.
                                            This Agreement (Including the exhibits and schedules hereto, each of which is Incorporated
                                            herein and made a part of this Agreement) constitutes the entire agreement and understanding
                                            of the parties hereto and terminates and supersedes any and all prior agreements, arrangements
                                            and understandings, both oral and written, express or implied, between the parties hereto
                                            concerning the subject matter of this Agreement.

 

    
	(Initials)
	 10 of 11	 

 

     

    

 

IN WITNESS WHEREOF, the parties hereto
have executed and entered Into this Exclusive Distribution Agreement as the date last signed below.

 

	AURASTEM TECHNOLOGIES, LLC	 	SUNEVA MEDICAL, INC
	 	 	 
	By	/s/ Bradford Conlan	 	By	/s/ Preston Romm
	Name:	Bradford Conlan	 	Name:	Preston Romm
	Title:	CEO	 	Title:	CEO
	 	 	 	 	 
	Date: November 21, 2018	 	Date: November 29, 2018

 

    
	(Initials)
	 11 of 11Exhibit 10.36

 

 

Distribution
Agreement

 

This AGREEMENT (‘Agreement’) is
made on 20 March 2020 between:

 

Sinclair Pharma US
Inc., a company established and existing under the laws of California, USA, having its place of business at 1 Technology Drive, Unit
134, Irvine, CA 92618, USA (‘Company’);

 

and

 

Suneva Medical, Inc.,
a company established and existing under the laws of Delaware, USA, having its principal place of business at 5870 Pacific Center Blvd.,
San Diego, CA 92121, USA (‘Distributor’).

 

WHEREAS

 

		(A)	Company has the rights to appoint distributors for the Products
(as defined below);

 

		(B)	Company wishes to grant to the Distributor sole and exclusive rights to distribute the Products in the
Territory (as defined below) on the terms and conditions of this Agreement; and

 

		(C)	Distributor is willing and able to provide a competent and capable infrastructure for such purposes in
such Territory.

 

Now, therefore, the Parties
to this Agreement, in consideration of the mutual covenants and undertakings herein contained, agree as follows:

 

		1.	DEFINITIONS

 

In this Agreement:

 

		1.1	‘Agreement’ means the agreement between the Parties constituted by this document including
all Schedules and Appendices;

 

		1.2	‘Affiliate’ means with respect to a Party, any person, corporation, firm, joint venture
or other entity, which directly or indirectly (whether or not through intermediates) Controls, is Controlled by or is under common Control
with such Party;

 

		1.3	‘Applicable Laws’ means all laws, enactments, regulations, statutes, industry codes,
binding judgements, economic, trade or financial sanctions and decisions of any court, tribunal or body and/or any legally binding rules
or polices of any regulatory body (including a Relevant Authority) which are in force from time to time and applicable to a Party and
the performance of its obligations under this Agreement;

 

		1.4	‘Business Day’ means a day (other than a Saturday, Sunday or public holiday in England
or New York) when banks in both London and New York are open for business;

 

		1.5	‘cGMP’ means the standards established by FDA or its successor and any governmental
agency in the Territory for current Good Manufacturing Practices;

 

		1.6	 ‘Company Corporate Packaging’ means the packaging and labelling used as standard by
the Company for the Products;

 

		1.7	‘Competing Product’ means any suture based aesthetic product. For the avoidance of
doubt, Competing Product shall not include any products being sold by the Distributor as at the Effective Date, including Bellafill or
any developments of such products;

 

    Page 1 of 34

    

    

 

		1.8	‘Confidential Information’ means
all information that is disclosed or made available by or on behalf of a Party (the ‘Disclosing Party’) to the other
Party (the ‘Receiving Party’) in connection with this Agreement, whether in writing, orally, visually or otherwise,
and whether before or after the Effective Date. Without limiting the generality of the foregoing, Confidential Information of a Party
shall include all ‘Confidential Information’ (as such term is defined in the Confidentiality Agreement) disclosed or made
available by or on behalf of such Party to the other Party pursuant to the Confidentiality Agreement.

 

		1.9	‘Confidentiality Agreement’
                                            means the confidentiality agreement between the Parties dated 11th August
                                            2017;

 

		1.10	‘Control’ means, in relation to a legal person, the direct or indirect ownership of
more than 50 per cent of the voting capital or similar right of ownership of that person or the legal power or the ability to direct the
affairs, general management or policies of another person, whether by virtue of the ownership of shares, contract or otherwise;

 

		1.11	‘Controller,’ ‘Data Subject,’ ‘Personal Data’ and ‘Processing’
(and its derivatives) shall each have the meaning given in the GDPR;

 

		1.12	‘Data Protection Laws’ means:

 

		(a)	Regulation (EU) 2016/679 of the European Parliament and of the Council on the protection of natural persons
with regard to the processing of Personal Data and the free movement of such data (GDPR);

 

		(b)	the UK Data Protection Act 2018 and any subsequent Act or Regulation replacing or amending the same;

 

		(c)	all other applicable laws relating to or impacting on the processing of Personal Data and privacy, including
any such laws in the Territory.

 

		1.13	‘Damages’ means any loss, damage, liability (whether arising out of fault, strict liability
or otherwise), obligation, fine, judgment for damages, arbitration award, settlement amount, penalty or claim and all reasonable costs
and expenses (including the fees and expenses of professional advisers) related thereto;

 

		1.14	‘Delivery’ means delivery pursuant to Clause 4.1;

 

		1.15	‘Due Date’ has the meaning set out in Clause 6.2;

 

		1.16	‘Effective Date’ means the date that appears at the beginning of this Agreement;

 

		1.17	‘FDA’ means United States Food and Drug Administration or its successor;

 

		1.18	‘FEFO’ means the principle of ‘first expired, first out’ in respect of the shelf life of the Products;

 

		1.19	‘Force Majeure Event’ means an event that results from causes beyond a party’s
reasonable control and unable reasonably to be planned for or avoided such as fires, floods, earthquakes, embargoes, shortages, failures
or delays in supplies, epidemics, quarantines, war, acts of war (whether war is declared or not), acts of terror, insurrections, riots,
civil commotion, or strikes, lockouts or other labour disturbances;

 

    Page 2 of 34

    

    

 

		1.20	‘Good Industry Practice’ means, at any time during the Term, the exercise of that degree
of care, prudence, efficiency, foresight, diligence, skill and timeliness which would reasonably and ordinarily be expected from a skilled,
trained, professional and experienced person engaged in the same type of undertaking and / or providing services similar to the undertaking
or services described herein under the same or similar circumstances;

 

		1.21	‘Import
                                            Licence’ has the meaning set out in Clause 9.3;

 

		1.22	‘Insolvency Event’ means in relation to a Party (the “Affected Party”),
where such Affected Party ceases carrying on its business, is adjudicated insolvent, files a voluntary petition in bankruptcy, or has
an involuntary petition for bankruptcy filed against it, which involuntary petition is not dismissed within 90 days, if an order is made
or a resolution is passed for the winding up, dissolution or liquidation of the Affected Party (other than voluntarily for the purpose
of solvent amalgamation or reconstruction), if a liquidator, administrator, administrative receiver, receiver, trustee or similar agent
is appointed in respect of all or substantially all of the Affected Party’s assets or business, if the Affected Party makes any
composition with or general assignment for the benefit of its creditors or if the Affected Party takes or suffers any similar, equivalent
or analogous action in any jurisdiction;

 

		1.23	‘Initial Term’ has the meaning given to it in Clause 14.1;

 

		1.24	‘Intellectual Property Rights’ means all intellectual and industrial property rights
of any kind whatsoever that relate to the Products including the Website, the Patents and the Trade Marks and any other relevant patents,
supplementary protection certificates, rights in know-how, registered trade marks, registered designs, models, unregistered design rights,
unregistered trade marks, rights to prevent passing off or unfair competition and copyright (whether in drawings, plans, specifications,
designs and computer software or otherwise), database rights, topography rights, any rights in any invention, discovery or process, and
applications for and rights to apply for any of the foregoing in each case in the United Kingdom and all other countries in the world
and together with all renewals, extensions, continuations, divisions, reissues, re-examinations and substitutions or such rights or applications
whether vested, contingent or future, owned by or licensed to the Company (or one of its Affiliates) in relation to the Products wherever
existing;

 

		1.25	‘Minimum Purchase Order Quantities’ means minimum order quantities for each Purchase
Order as specified as such in Schedule B as may be updated by the Parties from time to time on mutual written agreement;

 

		1.26	‘Minimum Purchase Obligations’ or ‘MPOs’ means in respect of any Quarter
the minimum amount of each Product that Distributor is obliged to purchase from the Company in that Quarter in accordance with Clauses
3.5 and 3.6, it being agreed that Product that is purchased but subsequently returned shall not be counted when calculating the amounts
purchased by the Distributor unless such Product is rejected because it does not meet the specifications set out in the Registration or
is not manufactured according to Applicable Law (in which case such non-conforming or non-compliant Product shall be counted when calculating
the amounts purchased by the Distributor);

 

		1.27	‘Parties’ means Company and Distributor and ‘Party’ means either
of them as the context indicates;

 

    Page 3 of 34

    

    

 

		1.28	‘Patent(s)’ means the patents and patent applications, short particulars of which are
set out in Schedule C, granted patents issuing from such applications and any supplementary protection certificates granted in
respect of the Products and all other future applications derived from said applications in any territory, which have any claims covering
the Products;

 

		1.29	‘Product’ means the products manufactured and packaged under the Trade Marks in the
form, dosage and presentation and for the indications detailed in Schedule A hereto;

 

		1.30	‘Purchase Order’ means a purchase order to be submitted by Distributor to Company pursuant
to Clause 3.3;

 

		1.31	‘Quarter’ means each three month period in each Year. Q1 spans 1 January – 31
March, Q2 spans 1 April – 30 June, Q3 spans 1 July - 31 September and Q4 spans 1 October – 31 December (in each case, the
dates are inclusive);

 

		1.32	‘Registration’ means in relation to Product any official approval, authorisation or
licence, including, if applicable, approval of Product’s selling prices and/or any social security approval, that is required in
order to permit the lawful distribution, marketing, promotion and/or sale of that Product in the Territory;

 

		1.33	‘Relevant Authority’ means all governmental bodies or agencies that are responsible
for the granting of any Registration required in the Territory;

 

		1.34	‘Representatives’ means, in relation to each Party, its Affiliates, its officers and
employees and the officers and employees of its Affiliates and its (and its Affiliates’) professional advisers;

 

		1.35	‘Sales & Marketing Plan’
                                            means the sales & marketing plan relating to Products as prepared by Distributor
                                            in accordance with Clause 5.5;

 

		1.36	‘Sale Transaction’ has the meaning given to it in
                                            Clause 18.7;

 

		1.37	‘Shared Data’ means Personal
                                            Data in respect of which both the Company and the Distributor are Controllers under Data
                                            Protection Laws;

 

		1.38	‘Specifications’ shall
                                            mean the specifications of the Product as set out in Schedule A which may be amended
                                            from time to time in accordance with Clause 8.4;

 

		1.39	‘Subcontractor’ means
                                            any Affiliate, agent, delegate, subcontractor or other person (other than an employee) who
                                            performs services for or on behalf of a Party in connection with the performance of such
                                            Party’s obligations under this Agreement;

 

		1.40	‘Supply Prices’ means,
                                            subject to Clause 6.6, the prices at which the Products are to be supplied by Company to
                                            Distributor as set out in Part B1 of Schedule B;

 

		1.41	‘Tax’ means any federal, local and/or other rates, taxes, levies, fees, assessments,
impositions or charges of any kind whatsoever, together with any interest and any penalties or additions and regardless of whether compliance
with such taxation regime is compulsory or voluntary with respect thereto, including any net income, gross income, gross receipts, sales,
use, ad valorem, transfer, franchise, profits, license, service, service use, value added, withholding, excise, severance and documentary;

 

    Page 4 of 34

    

    

 

		1.42	‘Term’ means the period commencing on the Effective Date and ending on the termination
or expiry of this Agreement;

 

		1.43	‘Territory’ means the countries or areas specified in Schedule F;

 

		1.44	‘Trade Marks’ means the registered trade marks and pending trade mark applications
and unregistered trade marks as set out in Schedule C and any further trade marks that the Company may permit the Distributor to
use in the Territory in respect of the Products by express notice in writing;

 

		1.45	‘Website’ means Sinclair’s website at www.instalift.com; and

 

		1.46	‘Year’ means a period of twelve (12) months (or part of such period in respect of the
12-month period in which this Agreement is terminated), where Year 1 shall commence on the Effective Date and end on the day immediately
prior to the first anniversary of the Effective Date and all subsequent Years shall be the twelve (12) month period commencing on the
anniversary of Year 1 and each subsequent anniversary.

 

		2.	APPOINTMENT

 

		2.1	Subject to the terms and conditions of this Agreement, Company hereby grants to the Distributor the sole
and exclusive right and licence during the Term to act as Company’s exclusive distributor and to import, distribute, promote, market
and sell Product in the Territory and Distributor hereby agrees to act in that capacity. For the avoidance of doubt, other than through
the Distributor, the Company shall not itself sell, supply, distribute or otherwise make available any Products in the Territory.

 

		2.2	Company undertakes that it shall not, other than through Distributor under this Agreement, as provided
in this Agreement or as otherwise expressly agreed by Distributor in writing, at any time during the Term, directly or indirectly, on
its own behalf or on behalf of or by, with or through any Affiliate or any other company or person:

 

		2.2.1	appoint any distributor, agent or other representative in the Territory in relation to the Products;

 

		2.2.2	be engaged, concerned or interested in the sale, supply, or distribution of the Products in the Territory;
or

 

		2.2.3	sell, supply, distribute or otherwise make available any Products to any person if Company or its Affiliate
knows or has reason to know that such Products will be resold, supplied or distributed in the Territory.

 

		2.3	Distributor shall not obtain supplies of Product for sale or resale in the Territory during the Term except
from the Company or from such third party as notified to the Distributor by the Company in writing as being authorised to supply the Product
to the Distributor. Distributor acknowledges that Company may grant rights to other persons to distribute the Product outside the Territory
but unless and until it does so the Company reserves exclusivity in all countries outside of the Territory for itself or its Affiliates.

 

		2.4	Distributor undertakes not to seek customers or to promote,
distribute or offer for sale the Product or establish or maintain any branch or distribution depot for the Product in any country that
is outside the Territory. The Distributor shall not represent itself as an agent of Company for any purpose, pledge Company’s credit,
give any condition or warranty on Company’s behalf, make any representation on Company’s behalf nor commit Company to any
contracts nor incur any liability on behalf of the Company. The Distributor shall not, without the prior written consent of the Company,
make any promises or guarantees in respect of the quality, efficacy or manufacture of the Product beyond those contained in the promotional
material provided by the Company (or approved by the Company under Clause 5.2) except as necessary to ensure compliance with Applicable
Law and the applicable Registration.

 

    Page 5 of 34

    

    

 

		2.5	The Distributor shall not (a) register in its own name nor use any trade marks or trade names which are
similar to or might be confused with the Trade Marks or (b) use in connection with the activities contemplated by this Agreement or apply
to any Product any trade marks or trade name of its own other than the Distributor’s corporate name and logo which application shall
be subject to the prior written approval of the Company.

 

		2.6	Subject to Section 13, the Company hereby grants to the Distributor a royalty-free, non-exclusive, non-transferable,
non-assignable (subject to Clause 18.7.1 and 18.7.2), licence during the Term under the Intellectual Property Rights and Registrations
solely to use, sell, promote, market and distribute the Products in the Territory and to import of Products into the Territory pursuant
to the terms of this Agreement with the right to sub-licence to any sub-distributor permitted pursuant to Clause 18.7 on the same terms
as the foregoing.

 

		2.7	Company shall be responsible for and shall pay the cost of any royalty and milestone payments due to any
third party as committed to by the Company or any of its Affiliates (including former owners of any rights in the Products) in relation
to the sale of Products in the Territory and shall indemnify, keep indemnified and hold harmless Distributor and its Affiliates and permitted
sub-distributors during the Term and any time thereafter in relation to any Damages in connection with or in relation to the payment of
any such royalty and/or milestone payments.

 

		3.	FORECASTS, ORDERS AND MINIMUM QUANTITY

 

		3.1	Distributor shall each month, for the duration of the Term of the Agreement (by no later than the seventh
day of the relevant month), provide to the Company a rolling twelve (12) month forecast detailing its good faith, estimated requirements
for Products (the ‘Product Forecast’). The Product Forecast shall be contained in the Company’s template set
out in Schedule I or such other format as the Parties may agree (the ‘Product Forecast Template’). It is acknowledged
that the Distributor’s Product requirements in respect of the first three (3) months of each Product Forecast (the ‘Initial
Three (3) Month Period’) shall be deemed fixed and shall not be capable of being amended by Distributor. Accordingly, Distributor
shall be obligated to purchase all Products referred to in the Initial Three (3) Month Period of each Product Forecast (including, for
the avoidance of doubt, the first Product Forecast provided by Distributor to Company pursuant to this Agreement) unless otherwise agreed
in writing by Company. The first Product Forecast shall be provided by Distributor to the Company within thirty (30) days of the Effective
Date. Delivery of a Product Forecast to Company does not constitute an order.

 

		3.2	Distributor acknowledges that Company’s ability to be able to meet demand for Products depends on
timely delivery by Distributor of the Product Forecast each month. The Company shall not be responsible for late Delivery if and to the
extent caused by Distributor’s failure to comply with the forecasting provisions set out in this Section 3.

 

    Page 6 of 34

    

    

 

		3.3	Orders for purchases of Product shall be submitted to Company
in writing in accordance with Schedule D (each being a ‘Purchase Order’), and shall not bind Company until
confirmed in writing by Company. Distributor shall place its first Purchase Order within thirty (30) days of the Effective Date. Company
shall use reasonable endeavours to confirm to Distributor whether a Purchase Order is accepted within ten (10) Business Days of receipt
and at the same time shall specify the Delivery date. Orders shall not usually be available for Delivery until twelve (12) weeks after
this confirmation (or longer if the relevant orders exceeds the Product Forecast by 20% or more). Once a Purchase Order is confirmed
by the Company in writing, it shall constitute a firm order and cannot be cancelled by the Distributor or the Company. Company shall
use its reasonable endeavours to meet the Delivery dates confirmed by it for all orders for Product. The Company shall not be responsible
for late Delivery if and to the extent caused by any breach by the Distributor of its obligations under this Agreement.

 

		3.4	The Company reserves the right to refuse Purchase Orders for Products which do not meet the Minimum Purchase
Order Quantities per order for Product.

 

		3.5	During the Initial Term, the Distributor shall, in each Quarter, place Purchase Orders for Product from
the Company in amounts that equal or exceed the MPOs in respect of each such Quarter as set out in Part B2 of Schedule B.

 

		3.6	Following expiry of the Initial Term, the Distributor shall place Purchase Orders for Product from the
Company in amounts that equal or exceed MPOs determined in accordance with the following:

 

		3.6.1	the MPOs will be set separately for each Year and corresponding Quarters, commencing after expiry of the
Initial Term (each such Year being referred to as a ‘New Year’);

 

		3.6.2	not less than six (6) months prior to the start of a New Year, the Parties will discuss and seek to agree
(each acting reasonably and in good faith in reaching such agreement) the MPOs in respect of that New Year (broken down by Quarters) such
agreement to be evidenced in writing and signed by both Parties; and

 

		3.6.3	if by the start of any New Year the Parties have not agreed the MPOs in respect of that New Year (including
all four Quarters within that New Year) the Minimum Purchase Obligations for that New Year shall be deemed to be the MPOs for the immediately
preceding Year (broken down by Quarter).

 

		3.7	If the Company determines that it is required to withdraw any of the Products from the market in the Territory
upon safety grounds or due to Applicable Laws or infringement of third party Intellectual Property Rights, it will where reasonably practicable
consult with the Distributor and the Parties shall co-operate in good faith to try to find an alternative solution to, wherever possible,
avoid such withdrawal or find a suitable work around. If the Parties cannot reach agreement on any matter referred to in this Clause 3.7,
the Company shall provide to the Distributor as much notice of such withdrawal as is in the circumstances reasonably practicable.

 

		3.8	If the Company’s need to withdraw the Product upon safety grounds or due to Applicable Laws or infringement
of third party Intellectual Property Rights has been caused by the negligence of or breach of this Agreement by the Distributor or its
Representatives, the Company shall be entitled to withdraw the Product at its discretion without liability to the Distributor.

 

    Page 7 of 34

    

    

 

		4.	SUPPLY AND DELIVERY

 

		4.1	Unless otherwise agreed by the Parties in writing, Product supplied under this Agreement is sold on an
Ex Works basis (as defined in the International Chamber of Commerce’s Incoterms 2010) at the Supply Price at such location as detailed
in Schedule B.

 

		4.2	Risk of loss or damage to any lot of Product shall pass to
Distributor on the earlier of (i) three (3) Business Days after notification to Distributor of release of the lot of Product and availability
for collection and (ii) the date of actual collection of such lot of Product.

 

		4.3	Company shall notify the Distributor in writing as soon as a lot of Product is ready for delivery and
provide all the necessary shipping information and documentation.

 

		4.4	If the Distributor has not arranged for the Products to be collected within ten (10) Business Days of
the Company notifying the Distributor and making available all necessary information and documentation in accordance with Clause 4.3,
the Company shall continue to store the lot and shall be entitled to recharge the reasonable additional storage costs incurred by the
Company per pallet per day for storing the Products (as supported by documentary evidence to be made available to the Distributor).

 

		4.5	Distributor shall keep throughout the Term a stock of Product reasonably estimated to be adequate to meet
market demand and to cover possible shortages in the supplies of Product in the Territory, such stock to correspond to at least three
(3) months’ average sales in the Territory.

 

		4.6	Distributor shall visually inspect each lot of Product promptly following receipt and promptly inform
Company in writing of any defects or issues without unreasonable delay, stating the reasons as well as the invoice, Purchase Order and
lot numbers. Defects that are clearly visible on an initial inspection shall be notified within five (5) Business Days from receipt of
the relevant Product by Distributor at its designated warehouse.

 

		4.7	For any latent defects in a Product or any defects that were not seen or could not reasonably have expected
to have been seen on an initial inspection, the Distributor shall give the Company notice in writing of such defect (together with the
relevant invoice, Purchase Order and lot numbers) and rejection of the relevant shipment no later than five (5) Business Days from the
date of discovery of such defect. For the avoidance of doubt Company shall not be liable for defects to the extent arising from Distributor’s
or its Representatives’ negligence or breach of this Agreement, including failure to store, handle and receive Product in accordance
with the Registration.

 

		4.8	In the event of a disagreement between Company and Distributor
regarding whether the Product is defective which the Parties are unable to resolve within fourteen (14) days of receipt of notice by
the Company pursuant to Clause 4.6 or 4.7, appropriate samples of the relevant Product shall be submitted for analysis to an independent
expert testing laboratory mutually agreed to by Distributor and Company, or in the event that they cannot agree within seven (7) days
(each acting reasonably and in good faith), to an independent expert testing laboratory appointed by the Company. In any other case,
the dispute shall be resolved in accordance with Clause 18.17. The determination of such expert testing laboratory shall be conclusive
and binding on the Parties. The cost of analysis shall initially be shared equally by the Parties, but the Party whose view as to whether
the relevant lot of Product is or is not defective is found to be incorrect shall reimburse the other Party for the share of such cost
initially borne by the other Party.

 

    Page 8 of 34

    

    

 

		4.9	Title to each unit of Product supplied hereunder shall pass
to Distributor upon the earlier of (a) payment in full to Company of the Supply Price for such unit and (b) immediately prior to the
resale of such unit of Product by Distributor in the ordinary course of its business. For purposes of this Clause 4.9, “resale”
shall be deemed to occur on the earlier of shipment thereof by Distributor to the applicable purchaser or issuance of an invoice therefor
by Distributor to the applicable purchaser. Pending title passing, Distributor shall hold such unit of Product as bailee for Company
but may use or resell such unit of Product in the ordinary course of its business, provided that immediately prior to resale of such
unit of Product by Distributor in the ordinary course of its business, title to such unit of Product shall pass to Distributor. In the
event that this Agreement expires or is terminated prior to title to a unit of Product passing to Distributor and while such unit of
Product is still in the possession or control of Distributor, then upon such expiration or termination, Company may enter Distributor’s
premises where such unit of Product is stored and repossess such unit of Product. Until title to Product passes to Distributor, Distributor
shall take all reasonable care of Product and separately store it.

 

		4.10	If Company agrees that a lot of Product is defective or if a lot of Product is found to be defective by
an independent expert under Clause 4.8, Distributor may return such defective Product to Company at Company’s cost and expense,
or if Company so requests Distributor shall dispose of such Product at Company’s cost and in compliance with Company’s instructions
and in either case, Company shall as soon as reasonably possible provide non-defective replacement Products at no cost to Distributor
and shall issue a credit for shipping costs. To the extent that any defect or non-conformity is attributable to any act or omission of
the Distributor or its Representatives in breach of this Agreement or reasonable written instructions provided by Company, including but
not limited to the improper handling or use and/or failure to store, handle and receive the Product in accordance with the terms of this
Agreement and/or the Registration, Distributor shall promptly reimburse Company for the properly-incurred and documented cost of return
or disposal of the defective Product and in respect of the replacement Products, the properly-incurred and documented cost of shipping,
Tax and associated costs.

 

		4.11	The Company shall provide to the Distributor a total of one thousand two hundred (1,200) boxes of free
Product in each Year (which amount shall be reduced on a pro-rata basis in the event that any Year is less than twelve (12) months) for
training, education, demonstration and similar uses but in the event that the total Adjusted Supply Price received by the Company in a
Year is more than 5% less than that received by it in the previous Year it shall reduce the amount of free of charge Products by such
amount that it deems reasonable in the circumstances, acting in good faith in making such assessment.

 

		5.	PACKAGING AND MARKETING

 

		5.1	The Company and Distributor agree that the Company shall supply all Products in Company Corporate Packaging
that complies with the Registration, all Applicable Laws, and cGMP.

 

		5.2	Any information about the Products provided by Distributor
including all labels, leaflets and package inserts shall comply with the Registration, all Applicable Laws, and cGMP. Further, the Distributor
shall not make any representations or claims regarding the efficacy and/or safety of the Products which are not expressly included in
the Registration or expressly agreed to in writing by the Company, such consent not to be unreasonably withheld or delayed. Distributor
shall submit to the Company, for its prior written approval, all new promotional literature and advertising or other marketing material
for the Products in English. The Company shall be deemed to have approved such material if it does not object within fifteen (15) Business
Days of receipt of such submission provided that if Distributor uses the promotional literature and advertising of the Company without
modification (other than to add the name and address of the Distributor) then no such review by the Company shall be necessary. Distributor
agrees to make no representations in its promotional literature or otherwise in relation to the Products which are inconsistent with
or exceed those claims in the Registration or approved in writing by the Company.

 

    Page 9 of 34

    

    

 

		5.3	Distributor shall ensure that all promotional material shall be based on any marketing material provided
by the Company and that such material and promotional activity complies with Applicable Laws and the Registration.

 

		5.4	All marketing activities in the Territory shall be the responsibility of the Distributor.

 

		5.5	The Distributor shall submit its Sales & Marketing Plan to the Company to cover as a minimum the information
set out in Schedule J hereto (the ‘Sales & Marketing Plan Template’) (or such other information as agreed
in writing by Distributor and the Company) for Company’s approval (such approval not to be unreasonably withheld or delayed), within
one (1) month of the Effective Date and on an annual basis thereafter.

 

		5.6	The Distributor shall use commercially reasonable efforts to implement the approved Sales & Marketing
Plan. The Parties shall meet on a quarterly basis at such location as is agreed to review the Distributor’s implementation of such
plan.

 

		5.7	Distributor shall ensure that it does not do anything at any time in connection with any Product whether
during the Term or upon termination or expiry of this Agreement, which would reasonably be expected to damage in any way the goodwill
in the Intellectual Property Rights.

 

		5.8	Each Party undertakes to the other that it shall not wilfully take any action which would reasonably be
expected to damage the reputation of the Products and/or the other Party and/or its Affiliates.

 

		5.9	Distributor may, at its own cost, conduct studies with Product
provided that it has been previously authorised to do so in writing by Company, Company has approved the final protocol and study centre(s)
for such studies in advance and in writing and, if requested by Company, any study centre first executes a confidentiality undertaking
in a form acceptable to Company. Company may, in its sole discretion, provide reasonable quantities of Product free of charge for such
approved studies, but shall not be obliged to do so, and it shall not be liable for any expenses incurred by Distributor in connection
with such studies. In the event any such studies with the Product are permitted by the Company, the Distributor shall ensure that they
are conducted in the Territory in compliance with all local legal and regulatory requirements and Applicable Laws. All results and all
scientific and clinical data relating to Product (and any intellectual property rights therein or arising therefrom) generated by or
on behalf of the Distributor or any third parties in connection with any such studies shall belong to Company, and Distributor shall,
and shall procure that all third parties shall, take all steps required to vest (or, if necessary, assign) such rights in and to the
Company. Distributor shall promptly deliver to Company copies of all information arising out of such studies, and any new scientific
or clinical data relating to Product, as soon as it comes into its possession, including any adverse drug experiences derived from such
studies. Distributor shall indemnify Company in respect of any and all Damages arising in connection with such studies. The results of
any such studies shall not be published without the prior written consent of Company except to the extent required by Applicable Laws,
in which event Distributor shall promptly notify Company of such requirement and, to the extent practicable under the circumstances,
shall give Company a reasonable opportunity to review such publication prior to issuance.

 

    Page 10 of 34

    

    

 

		6.	PAYMENT TERMS

 

		6.1	Sales by Company to Distributor shall be made Ex Works (at the location detailed in Schedule B)
at the Supply Prices (which are exclusive of VAT). Distributor shall be solely responsible for and it shall bear and pay all Taxes and
other charges imposed by reason of its purchase, import and resale of Product.

 

		6.2	Company shall invoice Distributor upon Delivery. Distributor shall pay Company for Product ordered hereunder
within forty five (45) days of the date of invoice (“Due Date”) and payment shall be made by means of electronic transfer
in immediately available funds to such bank account as Company may direct from time to time. Unless otherwise agreed, the invoiced currency
shall be US Dollars ($). Time for payment shall be of the essence of this Agreement.

 

		6.3	If Distributor fails to pay within ten (10) Business Days of the Due Date any amount greater than five
hundred thousand US dollars ($500,000) which is payable to Company under this Agreement without such failure being the result of and to
the extent only of any good faith dispute referred to in Clause 6.4, then, without prejudice to Sections 12 and 14 of this Agreement and
any other rights and remedies that the Company may be entitled to under the Agreement or at law (including the right to claim interest),
the Company shall be entitled to immediately suspend all orders and deliveries of Product to Distributor until all outstanding and due
amounts have been received by Company in full.

 

		6.4	If the Distributor disputes any invoice in good faith, it shall give prompt notice to Company and the
Parties shall attempt in good faith to resolve the issue as soon as reasonably possible. In such event, Distributor shall pay such amount
of the invoice that is not in dispute and the Company shall continue to supply Products in accordance with the terms of this Agreement,
provided that if it is agreed or otherwise determined that all or any amount of the sum withheld by Distributor should be paid to Company,
that amount will accrue interest in accordance with Clause 6.5.

 

		6.5	Any amount due and not paid on the Due Date, including any disputed amount that is subsequently required
to be paid, will incur interest at the rate of 2% over the base rate of The Bank of England from time to time, commencing on the Due Date
and continuing until fully paid, whether before or after any judgment.

 

		6.6	The Distributor shall determine at its sole discretion the
price at which it shall sell the Products in the Territory. At the end of each Year the Distributor shall reconcile the Supply Price
paid by the Distributor to Company versus the price at which the Distributor sold the Products in the Territory to calculate the actual
supply price payable (‘Adjusted Supply Price’) and to this end Distributor shall provide such evidence as reasonably
requested by the Company detailing the average selling price (‘ASP’) of Products sold by it in the previous Year in
the Territory within thirty (30) days of Company’s request. In the event that the difference between the ASP and the Supply Price
is more than 55% then the Distributor shall pay the total aggregate of all such amounts that exceed 55% to the Company within thirty
(30) days of receipt of the Company’s invoice. In the event that the difference between the ASP and the Supply Price is less than
55% then the Company shall pay such amount to Distributor between the Supply Price and the ASP to ensure the Distributor receives 55%
gross margin, provided that in the event the ASP is lower than the base price for the relevant Product as detailed in Schedule B,
for the purposes of calculating the amount owed by the Company to Distributor pursuant to this Clause the ASP shall be assumed to be
the base price.

 

    Page 11 of 34

    

    

 

		7.	OBLIGATIONS OF COMPANY

 

		7.1	The Company shall:

 

		7.1.1	supply Products to Distributor during the Term which conform to the Specifications and the Registrations
and comply with cGMP and Applicable Laws;

 

		7.1.2	provide all marketing materials relating to the Product in the Territory that it has in its possession
as at the Effective Date at no additional cost to Distributor;

 

		7.1.3	at all times during the Term maintain the Registrations and comply with all reporting and other requirements
of Relevant Authorities in the Territory with respect to the Product;

 

		7.1.4	upon notice from Distributor of any unauthorised sales or distribution of Products in the Territory by
any third party use reasonable efforts to determine the source of such Products, and Distributor shall reasonably cooperate with such
efforts. If any distributor of Products appointed by Company or any of its Affiliates outside of the Territory is the direct or indirect
source of such Products sold or distributed in the Territory Company shall take reasonable corrective action including if necessary and
where permitted by Applicable Laws specific enforcement of the relevant terms of Company’s or its Affiliate’s agreement with
such distributor and/or termination of such distributor’s Product distribution rights;

 

		7.1.5	not (and shall procure that none of its Affiliates shall) during the Term directly or indirectly market,
sell, distribute or import any Competing Product in the Territory; and

 

		7.1.6	introduce and give the Distributor reasonable access to its existing key opinion leaders of the Products
in the Territory.

 

		8.	REGISTRATION OF THE PRODUCTS AND PRODUCT LICENCES

 

		8.1	The Company undertakes to the Distributor that it shall obtain and maintain at all times during the Term,
at Company’s sole cost and expense, the Registration for the Products in the Territory.

 

		8.2	Without limiting Company’s obligations under Clause 8.3, Distributor hereby undertakes that it shall:

 

		8.2.1	provide any available information in Distributor’s possession as required by the Company from time
to time in order for the Company to obtain or maintain the Registration in the Territory;

 

    Page 12 of 34

    

    

 

		8.2.2	promptly notify the Company of any issue that comes to the Distributor’s knowledge that will affect
the Registration and promptly act in accordance with any reasonable and lawful instructions of Company to the extent needed; and

 

		8.2.3	on Company’s reasonable request promptly provide such reasonable support and assistance to Company
as is necessary in order for any Registration in the Territory to be obtained and maintained.

 

		8.3	The Company hereby undertakes that it shall:

 

		8.3.1	maintain or cause to be maintained, at Company’s sole cost and expense, the Registration for the
Products in the Territory at all times during the Term; and

 

		8.3.2	promptly notify and at all times keep Distributor informed of all material actions and activities that
relate to or affect the Registration. In addition, each Party shall promptly notify the other Party upon becoming aware of any changes
or anticipated changes in the Applicable Laws relevant to the nature, manufacture, packaging, labelling, importation, storage, transportation,
advertising, promotion and/or sale of the Products in the Territory and shall notify the other Party immediately if it becomes aware that
any of the Products are or may be in breach of any Registrations, Import Licenses or Applicable Laws in the Territory.

 

		8.4	Company shall have the control and decision making authority on any updates and changes to the Specifications,
manufacturing process or technical documentation or change of manufacturing facility (collectively “Changes”) provided
that Company complies with any relevant change control procedures in relation to the Products agreed between the Parties and provided
further that prior to making any Changes, where such Changes are required to be notified to Relevant Authorities in the Territory, Company
shall notify Distributor of the proposed Changes and Distributor shall have the opportunity to comment on such Changes. Company shall
submit such Change to the Relevant Authorities in the Territory as required by Applicable Laws. Company shall only implement the Changes
after the Relevant Authorities in the Territory when required have approved such Changes.

 

		9.	OBLIGATIONS OF DISTRIBUTOR

 

The Distributor shall:

 

		9.1	use all reasonable endeavours to ensure that it only distributes the Products to medically qualified professionals
(where relevant as required by instructions for use (“IFU”)) (but allowing that Distributor’s Medical Affairs
personnel may respond to unsolicited inquiries about uses that are outside of the IFU) and require that all potential purchasers of the
Product attend the training programme (where required) established or approved by Company and complete such training before sale of Product
will be made by Distributor;

 

		9.2	in importing, promoting, marketing, selling and distributing Product in the Territory, comply, in all
material respects, with Applicable Laws and the conditions and requirements of the Registrations;

 

		9.3	obtain, maintain and comply with any and all import licences (‘Import Licences’) which
are necessary for the entry of the Products into the Territory;

 

    Page 13 of 34

    

    

 

		9.4	provide to Company on the 15th of every month during the Term of the Agreement (or the next Business Day
following the 15th, if the 15th falls on a non-Business Day), an accurate, full and detailed breakdown of the total amount of stock of
the Products it holds together with full details of all sales, returns, outstanding customer orders, in each case broken down by Product
and by SKU by country within the Territory. In addition, upon Company’s request from time to time, Distributor shall provide such
other information relating to the marketing, promotion, sale and distribution of Products in the Territory as Company may reasonably request;

 

		9.5	use its commercially reasonable efforts to market, promote, sell and distribute Product in the Territory
including but not limited to in accordance with the Sales & Marketing Plan;

 

		9.6	within thirty (30) days after the Effective Date and at all times thereafter during the Term, have sufficient
competent, skilled, trained and properly supervised personnel, as are necessary to ensure compliance with its obligations under this Agreement,
which personnel shall include the transfer upon the Effective Date from the Company to Distributor of five employees of the Company working
in the Territory to include four sales representatives and one medical affairs person the identity of such personnel to be agreed by the
Company and Distributor and in the event that any of these employees refuse to transfer to the Company or subsequently leave the employment
of the Distributor (with or without cause) the Distributor shall promptly replace them with personnel of at least the same experience
and expertise ;

 

		9.7	without prejudice to its other obligations under this Agreement, conduct its activities in accordance
with Good Industry Practice;

 

		9.8	promptly investigate any complaints, problems or claims relating to the Product that the Distributor receives
in accordance with Applicable Law and the Distributor’s complaint handling procedures as detailed in Schedule G. Company
shall promptly investigate any complaints, problems or claims relating to the Product that Company receives in accordance with Applicable
Law and Company’s complaint handling procedures. Each Party shall reasonably cooperate with the other Party in investigating any
such complaint, product or claim received by either Party;

 

		9.9	keep full and proper books of account and records showing
clearly all transactions and sales relating to Product in the Territory and shall, within thirty (30) calendar days of request by Company
grant the Company access to such books of accounts and records for inspection and / or provide copies of the same to the Company for
review;

 

		9.10	promptly inform Company of all enquiries or orders for Product from outside the Territory;

 

		9.11	ensure that the shipment and storage of Product is in full compliance with the labelled storage conditions
applicable to the Product and/or any other conditions notified to the Distributor by the Company from time to time and immediately provide
to Company evidence of compliance with such labelled storage conditions at any time upon request;

 

		9.12	permit Company and its representatives, upon at least ten (10) Business Days’ notice (such notice
may be given by email), a right of access to such facilities, employees and records relevant to the storage, analysis, import, promotion,
distribution and sale of the Product for the purpose of verifying compliance with Applicable Laws as well as with the terms of this Agreement;

 

    Page 14 of 34

    

    

 

		9.13	without prejudice to any other provision of this Agreement, including Company’s obligations under
Section 8, ensure that it has all registrations, licences, approvals or consents required to enable it to perform its obligations under
this Agreement (specifically excluding the Registrations in the Territory);

 

		9.14	not (and shall procure that none of its Affiliates shall) during the Term:

 

		9.14.1	acquire rights to any Competing Products; or

 

		9.14.2	in any other way acquire any Competing Products, whether through acquisition, licence or otherwise and
whether directly or indirectly;

 

in each case without
first obtaining the Company’s prior written consent; and

 

		9.15	not (and shall procure that none of its Affiliates shall) for a period of six (6) months from the date
of any termination of this Agreement by Company for Distributor’s uncured material breach pursuant to Clause 14.4 or by Company
pursuant to Clause 14.5 or 14.6 be directly or indirectly (and whether alone or in conjunction with or on behalf of any other person)
engaged, concerned or interested in the manufacture, sale, supply, promotion, distribution, research, development or commercialisation
of any Competing Product in the Territory. For clarity, this Clause 9.15 shall terminate and be of no further force or effect in the event
of expiry of this Agreement or in the event of termination of this Agreement by Distributor for Company’s uncured material breach
pursuant to Clause 14.4 or termination of this Agreement by Distributor pursuant to Clause 14.5 or 14.6; and

 

		9.16	not manufacture Product, directly or indirectly, and shall sell the Product only in such packaging as
supplied and/or approved by the Company and save to the extent approved in writing by the Company it shall not use any other trade marks,
symbol, logo, get-up, imagery or devices, other than the Trade Marks in promoting, distributing and selling the Product, except for the
Distributor’s corporate name and logo as expressly permitted pursuant to Clause 2.5.

 

		10.	ANTI-BRIBERY & TAX EVASION

 

		10.1	In connection with the performance of the Distributor’s obligations under this Agreement, Distributor
(and all its directors, officers and employees, where appropriate):

 

		10.1.1	shall comply with all Applicable Laws relating to anti-bribery and anti-corruption including, without
limitation, the United Kingdom’s Bribery Act 2010 and the United States of America’s Foreign Corrupt Practices Act 1977 (‘Anti-Corruption
Laws’);

 

		10.1.2	shall not offer, promise, give, request, agree to receive, receive or accept a bribe or financial or other
advantage or commit any corrupt act or authorise or permit the same to be done on its behalf;

 

		10.1.3	shall not engage in any activity, practice or conduct (or failure to act) which would constitute an offence
under sections 1, 2 or 6 of the Bribery Act 2010 if such activity, practice or conduct were carried out (or such failure to act occurred)
in the UK;

 

		10.1.4	shall not do or omit to do any act or thing which constitutes an offence under Anti-Corruption Laws;

 

    Page 15 of 34

    

    

 

		10.1.5	shall not do any act or thing that causes or may cause the Company to be in breach of any Anti-Corruption
Laws;

 

		10.1.6	shall comply (and procure that all of its officers, employees and agents and any other persons or entities
who perform services for the Distributor comply) with the Company’s anti-bribery policy from time to time (the ‘Policy’),
the Policy as at the date of this Agreement being set out in Schedule E;

 

		10.1.7	shall have and maintain in place throughout the Term its own policies and procedures to ensure compliance
with the Policy and all Anti-Corruption Laws and shall enforce them;

 

		10.1.8	shall promptly report to the Company:

 

		(a)	any request or demand for any bribe, inducement or other undue financial or other advantage of any kind
received by the Distributor in connection with the Agreement; and/or in writing, any dealing by the Company with (or employing or otherwise
engaging) a foreign public official (as defined in the Bribery Act 2010) in connection with the performance of its obligations under this
Agreement;

 

		(b)	any breach of this Clause 10.1 by the Distributor; and/or

 

		10.1.9	shall on request provide to the Company such information and evidence as may from time to time be required
by the Company to demonstrate the Distributor’s compliance with this Clause 10.1;

 

		10.1.10	shall keep detailed, accurate and up to date records showing all payments made by it in connection with
performing its obligations under this Agreement. The Distributor shall, within ten (10) Business Days of a request by the Company, allow
the Company and its representatives to inspect these records and take copies of them; and

 

		10.1.11	shall be responsible to the Company for the compliance of each of the Distributor’s Subcontractors
with the Subcontractor terms, and shall be directly liable to Company for any breach by any such Subcontractor of its relevant Subcontractor
terms.

 

		10.2	The Distributor represents to the Company that it has not been convicted of any offence under any Anti-Corruption
Law and undertakes to the Company that it will notify the Company immediately if it is under investigation for a suspected breach of or
convicted for breach of any Anti-Corruption Laws.

 

		10.3	The Distributor agrees that if:

 

		10.3.1	the Company discovers that the representation made in Clause 10.2 above is false; or

 

		10.3.2	the Distributor is convicted for an offence under any Anti-Corruption
Laws after execution of this Agreement, then the Company shall be entitled to terminate this Agreement immediately by giving written
notice to the Distributor.

 

    Page 16 of 34

    

    

 

		10.4	The Distributor hereby warrants that it and its Affiliates have not been (i) involved in any criminal
investigation, inquiry or enforcement proceedings in relation to tax evasion or, so far as the Distributor is aware, is/are likely to
become involved in such an investigation, inquiry or enforcement proceedings or (ii) engaged in or facilitated any tax evasion, or in
each case, permitted any of its directors, senior officers, employees, agents or intermediaries to do the same, and the Distributor and
its Affiliates have in place adequate procedures to prevent engagement in or facilitation of tax evasion by its directors, senior officers,
employees, agents and intermediaries.

 

		10.5	The Company hereby warrants that it and its Affiliates have not been (i) involved in any criminal investigation,
inquiry or enforcement proceedings in relation to tax evasion or, so far as the Company is aware, is/are likely to become involved in
such an investigation, inquiry or enforcement proceedings or (ii) engaged in or facilitated any tax evasion, or in each case, permitted
any of its directors, senior officers, employees, agents or intermediaries to do the same, and the Company and its Affiliates have in
place adequate procedures to prevent engagement in or facilitation of tax evasion by its directors, senior officers, employees, agents
and intermediaries.

 

		11.	TECHNICAL & VIGILANCE MATTERS

 

		11.1	The Parties shall each comply with Schedule G in relation
to vigilance matters and Schedule H in relation to technical and quality matters.

 

		11.2	Each Party certifies that it and its directors, officers, agents, Subcontractors and employees: (i) have
not been and are not currently excluded pursuant to 42 U.S.C. §1320a-7 or similar state exclusion authority, debarred, or otherwise
ineligible to participate in any Federal health care program as that term is defined in 42 U.S.C. §1320a-7b(f) or comparable state
programs; (ii) have not been convicted of a criminal offense related to the provision of health care items or services or any other offense
that may lead to exclusion under 42 U.S.C. §1320a-7 or similar state exclusion authority; or (iii) to its knowledge are not under
investigation or otherwise aware of any circumstances which may result in being excluded from participation in any Federal or state health
care program. Each party maintains an ongoing obligation to ensure the accuracy of this certification. If any change in circumstance occurs
to make this certification inaccurate, it must notify the other Party in writing immediately and such other Party shall have the right
to immediately terminate this Agreement if the above certification is or becomes untrue.

 

		11.3	Company represents and warrants to Distributor that:

 

		11.3.1	it has full capacity and authority to enter into and to perform this Agreement;

 

		11.3.2	it has taken all corporate actions necessary to enter into and perform this Agreement;

 

		11.3.3	this Agreement is executed by a duly authorised representative of Company with full power and authority
to bind it and that once executed this Agreement will constitute legal, valid and binding obligations on Company;

 

		11.3.4	there are no actions, suits or proceedings or regulatory investigations pending or, to Company’s
knowledge, threatened against or affecting Company before any regulatory body, court or administrative body or arbitration tribunal that
might affect the ability of Company to meet and carry out its obligations under this Agreement;

    Page 17 of 34

    

    

 

		11.3.5	Company has the full right and authority to grant the licenses and rights granted in this Agreement;

 

		11.3.6	all Products supplied to Distributor will have been manufactured in accordance with cGMP and Applicable
Laws and will, on the date of Release of such Product, conform to the Specifications and the description in the Registration;

 

		11.3.7	neither Company nor any of its Affiliates (i) is a party to any legal action, suit or proceeding related
to the Product or the Intellectual Property, (ii) has received written notice from any third party claiming that the manufacture, use,
sale, offer for sale or import of the Product infringes the patent or other intellectual property rights of any third party, except as
disclosed to Distributor in writing (including by email) prior to the Effective Date, and (iii) has received any written communication
from any third party threatening any action, suit or proceeding relating to the Product or the Intellectual Property, except as disclosed
to Distributor in writing (including by email) prior to the Effective Date.

 

		11.4	Distributor represents and warrants to Company that:

 

		11.4.1	it has full capacity and authority to enter into and to perform this Agreement;

 

		11.4.2	it has taken all corporate actions necessary to enter into and perform this Agreement;

 

		11.4.3	this Agreement is executed by a duly authorised representative of Distributor with full power and authority
to bind it and that once executed this Agreement will constitute legal, valid and binding obligations on Distributor; and

 

		11.4.4	there are no actions, suits or proceedings or regulatory investigations pending or, to Distributor’s
knowledge, threatened against or affecting Distributor before any regulatory body, court or administrative body or arbitration tribunal
that might affect the ability of Distributor to meet and carry out its obligations under this Agreement.

 

		12.	LIABILITY AND INSURANCE

 

		12.1	Subject to Clause 12.11 and except as expressly provided in this Agreement and to the fullest extent permitted
by law, neither Party makes any representations or warranties of any kind with respect to Products or any other part of this Agreement,
express or implied, written or oral, including any implied warranty of merchantability, suitability or fitness for a particular purpose
and all warranties, representations and conditions implied by law are excluded to the maximum extent permissible.

 

		12.2	Subject to Clause 12.11, neither the Company nor any of its Affiliates shall be responsible for any Damages
suffered by Distributor if and to the extent arising out of Distributor’s or its agents’ negligence or wilful acts or failure
to act in connection with the requirements of this Agreement regarding storage, handling, distribution, use or sale by Distributor of
the Product.

 

		12.3	Distributor shall indemnify, defend and hold harmless Company against any and all Damages to which Company
may become subject as a result of any claim, demand, action or other proceeding by any third party to the extent such Damages arise out
of or in connection with:

 

		12.3.1	the deliberate misconduct of or reckless behaviour or gross negligence of Distributor and/or any of its
Affiliates or Subcontractors; or

 

    Page 18 of 34

    

    

 

		12.3.2	Distributor’s breach of any warranty, representation, covenant or agreement made by Distributor
in this Agreement.

 

		12.4	Distributor is not obliged to indemnify Company under Clause 12.3 to the extent the Damage is:

 

		12.4.1	caused by the deliberate misconduct of or reckless behaviour or gross negligence of Company and/or any
of its Affiliates or Subcontractors; or

 

		12.4.2	caused by Company’s breach of this Agreement which does not result from a prior breach by Distributor.

 

		12.5	Company shall indemnify, keep indemnified and hold harmless the Distributor against any and all Damages
to which the Distributor may become subject as a result of any claim, demand, action or other proceeding by any third party to the extent
such Damages arise out of or in connection with:

 

		12.5.1	Distributor’s and/or its Affiliate’s or Subcontractor’s proper exercise of its rights
granted to it by the Company under this Agreement;

 

		12.5.2	any defect in the Products;

 

		12.5.3	the promotion, marketing, sale or distribution of the Product by or on behalf of Company in the Territory
prior to the Effective Date; or

 

		12.5.4	alleged or actual infringement of the intellectual property rights of a third party arising from the sale,
marketing or distribution of the Products by Distributor and/or any of its Affiliates or Subcontractors in the Territory.

 

		12.6	Except Company is not obliged to indemnify Distributor under Clause 12.5 to the extent the Damage is:

 

		12.6.1	caused by the deliberate misconduct of or reckless behaviour or gross negligence of Distributor and/or
any of its Affiliates or Subcontractors; or

 

		12.6.2	caused by Distributor’s breach of this Agreement which does not result from a prior breach by Company.

 

		12.7	If any third party makes a claim, or notifies an intention to make a claim, against a Party which may
reasonably be considered likely to give rise to a liability under Clause 12.3 or Clause 12.5 (a “Relevant Claim”),
the Party receiving the benefit of the indemnity (the “Indemnitee”) shall:

 

		12.7.1	as soon as reasonably practicable, give written notice of the Relevant Claim to the indemnifying Party,
specifying the nature of the Relevant Claim in as much detail as reasonably practicable;

 

		12.7.2	not make any admission of liability, agreement or compromise in relation to the Relevant Claim without
the prior written consent of the indemnifying party (such consent not to be unreasonably withheld or delayed);

 

		12.7.3	give the indemnifying party access at reasonable times (on
reasonable prior notice) to its premises and its officers, directors, employees, agents and to any relevant assets, accounts, documents
and records within the power or control of the Indemnitee, so as to enable indemnifying party to examine them and to take copies (at
the indemnifying party’s expense) for the purpose of assessing the Relevant Claim; and

 

    Page 19 of 34

    

    

 

		12.7.4	allow the indemnifying party exclusive conduct of any proceedings at the indemnifying party’s full
cost, and at the indemnifying party’s cost and subject to being fully indemnified and held harmless by the indemnifying party, take
such action as the indemnifying party may reasonably request to avoid, dispute, compromise or defend the Relevant Claim.

 

		12.8	Each Party agrees to procure and maintain in full force and effect with reputable insurers during the
Term and for a period of at least three (3) years following the expiry or termination of this Agreement, valid and effective insurance
policies in connection with its activities as contemplated herein. Each Party undertakes to provide to the other, upon such Party’s
request, a certificate evidencing such insurance cover, without prejudice to the preceding provisions of this Clause 12.8;

 

		12.8.1	Distributor shall insure all Product from the date of Delivery for an amount equal to or exceeding the
Supply Price and maintain general liability insurance (‘public liability’) of at least ten million US dollars ($10,000,000)
of coverage per occurrence; and

 

		12.8.2	Company shall, at its expense, carry product liability and comprehensive general liability insurance coverage
of at least ten million US dollars ($10,000,000) per occurrence.

 

		12.9	Subject to Clause 12.11, the liability of the Company to the Distributor in each calendar year in which
the event giving rise to the claim occurred under or in connection with this Agreement or the Product howsoever arising (whether under
tort including (negligence), breach of contract, statute, restitution under any indemnity or otherwise) shall (i) in the case of a product
liability claim not exceed ten million US dollars ($10,000,000) and (ii) in all other cases shall not exceed the higher of (a) three million
US dollars ($3,000,000) and (b) the total amount paid or payable by the Distributor to the Company under the Agreement in the Year in
which the event giving rise to the claim occurred. This Clause 12.9 shall not apply to any of the Company’s obligations under this
Agreement relating to the Intellectual Property Rights, confidentiality, compliance with any Applicable Laws (including Data Protection
Laws), the Registrations or indemnification with respect to third party claims, which shall not be subject to any cap.

 

		12.10	Subject to Clause 12.11, the liability of the Distributor
to the Company in each calendar year in which the event giving rise to the claim occurred under or in connection with this Agreement
or the Product howsoever arising (whether under tort including (negligence), breach of contract, statute, restitution under any indemnity
or otherwise) shall not exceed the higher of (a) three million US dollars ($,3,000,000) and (b) the total amount paid or payable by the
Distributor to the Company under the Agreement in the Year in which the event giving rise to the claim occurred. This Clause 12.10 shall
not apply to any of the Distributor’s obligations under this Agreement relating to the Intellectual Property Rights, confidentiality,
compliance with any Applicable Laws (including Data Protection Laws), the Registrations, or indemnification with respect to third party
claims, which shall not be subject to any cap.

 

		12.11	Neither Party excludes, restricts or limits its liability
under this Agreement for: death or personal injury caused by its negligence; fraud, (including fraudulent misrepresentation); under section
12 of the Sale of Goods Act 1979; or for any matter that cannot be limited, restricted or excluded by law.

 

    Page 20 of 34

    

    

 

		12.12	Subject to Clause 12.11, neither Party shall under any circumstances have any liability to the other Party
for any direct or indirect loss of profit, loss of revenue, loss of anticipated savings, loss of business, goodwill or reputation or any
indirect loss or damage arising out of or in relation to any of its obligations or duties under this Agreement.

 

		13.	INTELLECTUAL PROPERTY RIGHTS

 

		13.1	The Intellectual Property Rights are the exclusive property of Company and/or its Affiliates and Distributor
shall not seek to register or have registered any of the Intellectual Property Rights, and shall not display or use any of the Intellectual
Property Rights except in a manner previously approved by Company in writing; provided however no such prior written approval shall be
required for such use consisting solely of

 

		13.1.1	the sale or distribution of Product in packaging supplied by Company and bearing the Trade Marks; or

 

		13.1.2	the use of advertising or promotional materials supplied or approved by Company.

 

		13.2	Distributor shall discontinue any authorised use of the Intellectual Property Rights upon valid termination
of this Agreement by the Company.

 

		13.3	Each Party shall promptly inform the other Party of any infringement or suspected infringement of Company’s
Intellectual Property Rights in the Territory or any claim that any Product or the manufacture, import, use, sale or other disposal of
any Product within the Territory infringes the rights of any third party. Company shall in its absolute discretion, decide on the best
steps to be taken after having discussed the case with Distributor who shall, give all reasonable co- operation to Company at the Company’s
cost provided such costs are reasonably and properly incurred. The Company shall conduct and have sole control over any consequent action
that it deems necessary and the Company shall pay all costs in relation to that action and shall be entitled to all damages and other
sums that may be paid or awarded as a result of that action.

 

		13.4	Distributor undertakes to use the Intellectual Property Rights strictly in accordance with the provisions
of this Agreement in relation to Product and only in such manner and with such acknowledgement of proprietorship as from time to time
shall have been stipulated by Company and the Distributor shall not do, or omit to do, anything in its use of the Intellectual Property
Rights that would reasonably be expected to adversely affect their validity.

 

		13.5	Distributor shall sell Product in the same condition as it is received by it and shall not deface or alter
Product or its packaging, remove or modify any labels, instructions or identifying insignia applied to or furnished in connection with
Product or affix to Product or its packaging any labels or signs not previously approved in writing by Company.

 

		13.6	If the Trade Marks are unavailable for use in the Territory or any part thereof, the Parties shall agree
upon alternative trade marks to be used on Product and all rights, title and interest in and to such Trade Marks shall be the exclusive
property of the Company. The provisions of this Section 13 shall apply to such alternative trade marks in the same way as they apply to
the Trade Marks.

 

    Page 21 of 34

    

    

 

		13.7	Distributor shall, at the request of Company and at Company’s sole cost, promptly enter into any
document reasonably necessary for the recording, registration or safeguarding of the Company’s Intellectual Property Rights in the
Territory and take all steps and actions as reasonably required by the Company.

 

		13.8	Subject to Applicable Laws, nothing contained in this Agreement shall be construed as giving Distributor
the right to use the Intellectual Property Rights outside of the Territory or for any other product than Product and the Distributor acknowledges
that the Company may use, and/or license others to use, the Intellectual Property Rights in all jurisdictions outside of the Territory.

 

		13.9	Distributor acknowledges that the Company is the owner of the Intellectual Property Rights. Any goodwill
derived from the use by the Distributor or its Subcontractors of the Intellectual Property Rights shall belong to the Company and the
Distributor shall execute or procure the execution of any documents that Company may reasonably request to assign any such goodwill to
the Company.

 

		14.	DURATION AND TERMINATION

 

		14.1	This Agreement shall become effective on the Effective Date
and, subject to the provisions of this Section 14, shall remain in effect for a period of five (5) years from the Effective Date (the
‘Initial Term’) and shall continue thereafter unless and until terminated earlier in accordance with the terms of
this Agreement or by either party on giving to the other not less than ninety (90) days’ written notice such notice to be served
at any time but to expire at the end of the Initial Term or any time thereafter.

 

		14.2	Company undertakes and warrants to Distributor that if it sells or relinquishes control in any manner
or form the rights to any Product (including, without limitation, any Registration or Intellectual Property Rights) or sells or relinquishes
control to any part of its business involving one or more of the Products, it shall procure that this Agreement to the extent it applies
to that Product is novated to the buyer in its current form.

 

		14.3	Notwithstanding the provisions of Clause 14.1 the Company shall be entitled to terminate the rights and
obligations in this Agreement in so far as they relate to Canada, without penalty, upon giving to the Company not less than nine (9) months
prior written notice, such notice to be served at any time.

 

		14.4	Except as otherwise expressly set forth in Clause 14.5, a Party shall have the right to terminate this
Agreement upon written notice to the other Party if such other Party is in material breach of this Agreement and has not cured such breach
within 60 days (or, except as set forth in Clause 14.5(b), 30 days with respect to any breach of a payment obligation) after notice from
the terminating Party requesting cure of the breach. Any such termination shall become effective at the end of such 60-day (or, except
as set forth in Clause 14.5(b), 30-day with respect to any breach of a payment obligation) period unless the breaching Party has cured
such breach prior to the end of such period. Any right to terminate under this Clause 14.4 shall be stayed and the cure period tolled
in the event that, during any cure period, the Party alleged to have been in material breach shall have initiated legal action in accordance
with Clause 18.17 with respect to the alleged breach, which stay and tolling shall continue until such dispute has been resolved in accordance
with Clause 18.17.

 

    Page 22 of 34

    

    

 

		14.5	In addition to a Party’s right to terminate this Agreement in accordance with any other Clause of
this Section 14, a Party (or in the case of Clause 14.5(b), 14.5(c), 14.5(d) or 14.5(g) below, Company) shall have the right to terminate
this Agreement immediately upon written notice to the other Party (or in the case of Clause 14.5(b), 14.5(c), 14.5(d) or 14.5(g) below,
to Distributor) in the event that:

 

		(a)	the other Party is convicted of any violation of Anti-Corruption Laws;

 

		(b)	Distributor fails to pay an amount or instalment due under this Agreement on time where the total amount
due is five hundred thousand US dollars ($500,000) or higher (provided such amount is not the subject of a bona fide dispute) and provided
Company has given Distributor at least ten (10) Business Days’ notice that such amount is overdue and the payment has not been made
in this time;

 

		(c)	Distributor fails to comply with Applicable Laws in any material respect which leads to Registration of
a Product in the Territory being withdrawn by the Relevant Authority;

 

		(d)	Distributor fails to submit its Product Forecasts on or before the deadlines specified in this Agreement
on 3 occasions in any rolling twelve-month period during the Term, provided that a failure shall only be triggered on each occasion where
the Company has given written notice to the Distributor of a deadline being missed and the Distributor failing to provide the forecast
within five (5) Business Days of receiving such notice;

 

		(e)	the other Party or any of its Affiliates is found by a court of competent jurisdiction to have engaged
in or facilitated tax evasion in relation to this Agreement resulting in any offence under the Criminal Finances Act 2017;

 

		(f)	the other Party or any of its Affiliates or its Affiliates is found by a court of competent jurisdiction
to have committed any fraudulent act or fraudulent omission in relation to this Agreement resulting in any material adverse effect to
the first Party; or

 

		(g)	Distributor or any of its Affiliates or agents challenges the validity, enforceability, registration or
ownership of the Trade Marks or Intellectual Property Rights.

 

		14.6	Without prejudice to any other rights or remedy it may have under this Agreement or at law, if either
Party (the “Affected Party”) undergoes an Insolvency Event, then the Affected Party shall immediately notify the other
Party providing details of the Insolvency Event and such other Party may terminate this Agreement without penalty by giving immediate
written notice to the Affected Party.

 

		14.7	For the avoidance of doubt the exercise of any express right to terminate this Agreement for any cause
whatsoever shall be without prejudice to any and all rights and claims that shall, or may have accrued under the Agreement or otherwise
at law.

 

    Page 23 of 34

    

    

 

		15.	CONSEQUENCES OF TERMINATION

 

		15.1	Upon termination or expiry of this Agreement for any reason, the Company shall be entitled, but not obliged,
to purchase (or to require the Distributor to sell to the Company’s nominee) all and/or part of the Distributor’s remaining
stock of Products (‘Residual Stock’). The Company shall notify the Distributor in writing within fourteen (14) days
of the termination of this Agreement if it wishes to purchase any of the Residual Stock. The price payable by the Company or its nominee
for any Residual Stock so purchased shall be the fully landed costs of the items of Residual Stock to be so purchased which shall mean
the Supply Price plus all relevant duties and any Tax. If the Company does not wish to exercise this right or wishes to purchase part
of the Residual Stock only, the Distributor may in the six (6) months period immediately following termination of this Agreement (the
‘Sell-Off Period’) sell the remaining stocks and after expiry of the Sell-Off Period all rights to distribute, market
and sell the Product and all other licences granted pursuant to this Agreement shall immediately cease.

 

		15.2	Upon termination or expiry of the Agreement for any reason, the Distributor shall make and deliver to
the Supplier a complete and accurate inventory of the Distributor’s stocks of the Products as at the date of termination or expiry.
The Distributor shall update such inventory on a weekly basis during any Sell-Off Period.

 

		15.3	The valid exercise by Company of a termination right provided for under this Agreement shall not give
rise to any claim by Distributor against Company for loss of distribution rights, loss of goodwill or any similar loss as a result of
the valid termination of this Agreement.

 

		15.4	Upon expiration or termination of this Agreement for any reason whatsoever, except to the extent required
to fulfil its obligations or exercise its rights pursuant to Clause 15.1, or as otherwise directed by the Company in writing, Distributor
shall immediately cease any use of the Registration.

 

		15.5	Neither expiration nor any termination of this Agreement shall relieve either Party of any obligation
or liability accruing prior to such expiration or termination, nor shall expiration or any termination of this Agreement preclude either
Party from pursuing all rights and remedies it may have under this Agreement, at law or in equity, with respect to breach of this Agreement.
In addition, the Parties’ rights and obligations under Clauses 2.7, 6.5 and 13.2 and Sections 12, 14, 15, 16 and 18 of this Agreement
shall survive expiration or any termination of this Agreement.

 

		15.6	Following service of notice to terminate this Agreement the Company shall be entitled to reject any further
Purchase Orders.

 

		15.7	Except as provided in Clause 15.1, on termination of this Agreement by the Company the Distributor shall
immediately cease to act as and/or describe itself as the Company’s distributor, shall cease all sale of the Products and use of
the Intellectual Property Rights, shall return to the Company all of the Company’s information and Product literature and shall
destroy all letterhead, business cards and/or other business stationery which may bear the Trade Marks and/or the Company’s name
and/or any other Intellectual Property Rights.

 

		15.8	The Distributor is not permitted to build stocks of or take orders for the Products in anticipation of
the expiration or termination of this Agreement and the Company shall be entitled to reject any order it believes to be in breach of this
Clause 15.8.

 

    Page 24 of 34

    

    

 

		16.	PRODUCT RECALLS

 

		16.1	Each Party shall comply with the terms of Schedule H regarding all Product recalls. The Company
shall provide replacement Products and shall continue to supply Products in accordance with the terms of this Agreement as soon as reasonably
possible following such recall and the Parties shall work together in good faith to agree the best way of achieving this. The Company
shall not be liable to Distributor during this period for any failure to supply the Products, nor shall Distributor be liable to the Company
during this period for any failure to promote, market, sell or distribute the Products.

 

		17.	RIGHT OF FIRST NEGOTIATION

 

		17.1	Right of first negotiation in favour of Distributor

 

		17.1.1	Subject to Clauses 17.3 and 18.7, during the Term, in the event that Company or any of its Affiliates
desires to grant any person, other than the Company or its Affiliates, any rights (whether by license or asset sale, but specifically
excluding any proposed Sale Transaction) to commercialise any or all of the products of Company or any of its Affiliates in the Sinclair
Group (but excluding Huadong Medicine Company Ltd. and/or Huadong Medicine Aesthetics Investment (HongKong) Limited) in country(ies) in
the Territory (‘Territory Rights’), Company shall provide Distributor with written notice thereof, specifying the applicable
product(s) with respect to which it proposes to grant Territory Rights (each, a ‘Company Offered Product’) and the
country(ies) in the Territory in which Company or its Affiliate proposes to grant such Territory Rights (the ‘Company Offered
Country(ies)’), and hereby grants Distributor the right of first negotiation to obtain Territory Rights with respect to the
Company Offered Product(s) in the Company Offered Country(ies) (collectively, the ‘Offered Territory Rights’) in accordance
with this Clause 17.1. For clarity, Distributor’s right of first negotiation with respect to any Offered Territory Rights under
this Clause 17.1 applies to such Offered Territory Rights in their entirety – i.e., all (and not less than all) of the applicable
Company Offered Products in all (and not less than all) of the applicable Company Offered Country(ies).

 

		17.1.2	Distributor shall within thirty (30) days after receipt of such notice notify Company in writing either
that (a) Distributor is interested in negotiating for such Offered Territory Rights or (b) Distributor has no interest and therefore rejects
its right of first negotiation to obtain such Offered Territory Rights. If Distributor notifies Company within thirty (30) days that Distributor
desires to negotiate for such Offered Territory Rights, the Parties shall negotiate in good faith for up to ninety (90) days from such
notification regarding the terms pursuant to which Company would grant such Offered Territory Rights to Distributor. Failure by Distributor
to give notice of its interest or lack of interest in negotiating for such Offered Territory Rights within thirty (30) days after receipt
of written notice from Company as described in the first sentence of this Clause 17.1 shall be deemed to constitute a waiver by the Distributor
of its right of first negotiation with respect to such Offered Territory Rights. In addition, failure of the Parties to agree within such
90-day negotiation period shall be deemed to constitute rejection by Distributor of such Offered Territory Rights, subject to Clause 17.1.3.

 

    Page 25 of 34

    

    

 

		17.1.3	If Distributor waives or otherwise fails to exercise its
right of first negotiation with respect to such Offered Territory Rights, or if the Parties fail to agree within such 90-day negotiation
period, then Company shall be free to grant such Offered Territory Rights in their entirety – i.e.,
all (and not less than all) of the applicable Company Offered Products in all (and not less than all) of the applicable Company Offered
Country(ies) – to any third party, and Distributor shall have no further rights with respect to such Offered Territory Rights;
provided, however, that:

 

		(a)	if Distributor had exercised its right of first negotiation with respect to such Offered Territory Rights
but the Parties failed to reach agreement within the 90-day negotiation period, then:

 

		(i)	during the 12-month period beginning on the expiration of such negotiation period, Company shall not grant
such Offered Territory Rights to any third party on terms more favourable to such third party than those offered to Distributor without
first offering such Offered Territory Rights to Distributor on such more favourable terms for a period of thirty (30) days; and

 

		(ii)	if Company does not enter into a definitive agreement with a third party for the grant of such Offered
Territory Rights before the expiration of such 12-month period, then such Offered Territory Rights shall again become subject to this
Clause 17.1; and

 

		(b)	whether or not Distributor exercised its right of first negotiation with respect to such Offered Territory
Rights, if Company makes any modification to such Offered Territory Rights (i.e., adding or removing a product from the Company
Offered Products and/or a country from the Company Offered Country(ies)) and desires to grant any person, other than the Company or its
Affiliates, any rights to such Offered Territory Rights as so modified, such Offered Territory Rights as so modified shall be subject
to this Clause 17.1 to the same extent as were the original unmodified Offered Territory Rights.

 

		17.1.4	For clarity, Company’s obligation to provide Distributor
with a right of first negotiation under this Clause 17.1 shall apply individually to each product of Company and its Affiliates (excluding
Huadong Medicine Company Ltd. and/or Huadong Medicine Aesthetics Investment (HongKong) Limited) in each country of the Territory, and
Distributor’s waiver of or failure to exercise its right of first negotiation with respect to any particular product in any particular
country of the Territory shall not constitute a waiver of Distributor’s right of first negotiation under this Clause 17.1 with
respect to (i) that product in any other country in the Territory or (ii) any other product in any country of the Territory.

 

		17.2	Right of first negotiation in favour of Company

 

		17.2.1	Subject to Clauses 17.3 and 18.7, during the Term, in the
event that Distributor or any of its Affiliates desires to grant any person, other than the Distributor or its Affiliates, any rights
(whether by license or asset sale, but specifically excluding any proposed Sale Transaction) to commercialise any or all of the Distributor’s
or its Affiliates’ products in country(ies) outside of the Territory (‘Ex-Territory Rights’), Distributor shall
provide Company with written notice thereof, specifying the applicable product(s) with respect to which it proposes to grant Ex-Territory
Rights (each, a ‘Distributor Offered Product’) and the country(ies) outside of the Territory in which Distributor
or its Affiliate proposes to grant such Ex-Territory Rights (the ‘Distributor Offered Country(ies)’), and hereby grants
Company the right of first negotiation to obtain Ex-Territory Rights with respect to such Distributor Offered Product(s) in such Distributor
Offered Country(ies) (collectively, the ‘Offered Ex-Territory Rights’) in accordance with this Clause 17.2. For clarity,
Company’s right of first negotiation with respect to any Offered Ex-Territory Rights under this Clause 17.2 applies to such Offered
Ex-Territory Rights in their entirety – i.e., all (and not less than all) of the applicable
Distributor Offered Products in all (and not less than all) of the applicable Distributor Offered Country(ies).

 

    Page 26 of 34

    

    

 

		17.2.2	Company shall within thirty (30) days after receipt of such notice notify Distributor in writing either
that (a) Company is interested in negotiating for such Offered Ex-Territory Rights or (b) Company has no interest and therefore rejects
its right of first negotiation to obtain such Offered Ex-Territory Rights. If Company notifies Distributor within thirty (30) days that
Company desires to negotiate for such Offered Ex-Territory Rights, the Parties shall negotiate in good faith for up to ninety (90) days
from such notification regarding the terms pursuant to which Distributor would grant such Offered Ex-Territory Rights to Company. Failure
by Company to give notice of its interest or lack of interest in negotiating for such Offered Ex-Territory Rights within thirty (30) days
after receipt of written notice from Distributor as described in the first sentence of this Clause 17.2 shall be deemed to constitute
a waiver by the Company of its right of first negotiation with respect to such Offered Ex-Territory Rights. In addition, failure of the
Parties to agree within such 90-day negotiation period shall be deemed to constitute rejection by Company of such Offered Ex-Territory
Rights, subject to Clause 17.2.3.

 

		17.2.3	If Company waives or otherwise fails to exercise its right of first negotiation with respect to such Offered
Ex-Territory Rights, or if the Parties fail to agree within such 90-day negotiation period, then Distributor shall be free to grant such
Offered Ex-Territory Rights in their entirety – i.e., all (and not less than all) of the applicable Distributor Offered Products
in all (and not less than all) of the applicable Distributor Offered Country(ies) – to any third party, and Company shall have no
further rights with respect to such Offered Ex-Territory Rights; provided, however, that:

 

		(a)	if Company had exercised its right of first negotiation with respect to such Offered Ex-Territory Rights
but the Parties failed to reach agreement within the 90-day negotiation period, then:

 

		(i)	during the 12-month period beginning on the expiration of such negotiation period, Distributor shall not
grant such Offered Ex-Territory Rights to any third party on terms more favourable to such third party than those offered to Company without
first offering such Offered Ex-Territory Rights to Company on such more favourable terms for a period of thirty (30) days; and

 

		(ii)	if Distributor does not enter into a definitive agreement with a third party for the grant of such Offered
Ex-Territory Rights before the expiration of such 12-month period, then such Offered Ex-Territory Rights shall again become subject to
this Clause 17.2; and

 

    Page 27 of 34

    

    

 

		(b)	whether or not Company exercised its right of first negotiation with respect to such Offered Ex-Territory
Rights, if Distributor makes any modification to such Offered Ex-Territory Rights (i.e., adding or removing a product from the
Distributor Offered Products and/or a country from the Distributor Offered Country(ies)) and desires to grant any person, other than the
Distributor or its Affiliates, any rights to such Offered Ex-Territory Rights as so modified, such Offered Ex-Territory Rights as so modified
shall be subject to this Clause 17.2 to the same extent as were the original unmodified Offered Ex-Territory Rights.

 

		17.2.4	For clarity, Distributor’s obligation to provide Company with a right of first negotiation under
this Clause 17.2 shall apply individually to each product of Distributor and its Affiliates in each country outside of the Territory,
and Company’s waiver of or failure to exercise its right of first negotiation with respect to any particular product in any particular
country outside of the Territory shall not constitute a waiver of Company’s right of first negotiation under this Clause 17.2 with
respect to (i) that product in any other country outside of the Territory or (ii) any other product in any country outside of the Territory.

 

		17.3	For clarity, neither Clause 17.1 nor Clause 17.2 shall apply to any proposed Sale Transaction with respect
to a Party.

 

		18.	MISCELLANEOUS PROVISIONS

 

		18.1	The relationship between Company and Distributor established by this Agreement is that of independent
contractors, and neither Party shall hold itself out as an agent of the other Party. Nothing contained in this Agreement shall be construed
to:

 

		18.1.1	give either Party the power to direct and control the day-to-day activities of the other; or

 

		18.1.2	constitute the Parties as partners, joint venturers, co-owners or otherwise as participants in a joint
or common undertaking; or

 

		18.1.3	constitute either Party as an agent, employee or legal representative of the other Party.

 

		18.2	Any or all of the activities or obligations of a Party referred to or contemplated in this Agreement may
be carried out on such Party’s behalf by an Affiliate of such Party as may be notified to the other Party.

 

		18.3	Neither Party shall have any power or authority to bind the other Party in any manner and shall not hold
itself out as the agent of the other Party for any purpose.

 

		18.4	Confidentiality

 

		18.4.1	Except to the extent expressly authorized by this Agreement
or otherwise agreed in writing by the Parties, the Receiving Party agrees that, during the Term and for five (5) years thereafter, such
Party shall keep confidential and shall not publish or otherwise disclose and shall not use for any purpose other than as expressly provided
for in this Agreement any Confidential Information of the Disclosing Party. The Receiving Party may use such Confidential Information
only to the extent required to accomplish the purposes of this Agreement. The Receiving Party shall use at least the same standard of
care as it uses to protect proprietary or confidential information of its own to ensure that its employees, agents, consultants and other
representatives do not disclose or make any unauthorized use of the Confidential Information. The Receiving Party shall promptly notify
the other Party upon discovery of any unauthorized use or disclosure of the Confidential Information.

 

    Page 28 of 34

    

    

 

		18.4.2	The Receiving Party’s obligations under this Clause 18.4 shall not apply to any information which
the Receiving Party can prove by competent evidence:

 

		(a)	is now, or hereafter becomes, through no act or failure to act on the part of the Receiving Party, generally
known or available;

 

		(b)	is known by the Receiving Party at the time of receiving such information, as evidenced by its records;

 

		(c)	is hereafter furnished to the Receiving Party by a third party, as a matter of right and without restriction
on disclosure; or

 

		(d)	is independently discovered or developed by the Receiving Party without the use of Confidential Information
of the other Party.

 

		18.4.3	The Receiving Party may disclose Confidential Information of the Disclosing Party as expressly permitted
by this Agreement or if and to the extent such disclosure is reasonably necessary in the following instances:

 

		(a)	complying with applicable court orders, Applicable Laws, or the listing rules of any exchange on which
such Party’s securities are traded;

 

		(b)	in the case of Company, complying with Company’s reporting obligations to Relevant Authorities in
the Territory with respect to the Product;

 

		(c)	disclosure to Affiliates, actual and potential Subcontractors, employees, officers, directors or agents
of the Receiving Party who have a need to know such information in order for the Receiving Party to exercise its rights or fulfil its
obligations under this Agreement, provided, in each case, that any such Affiliate, actual or potential Subcontractor, employee, officer,
director or agent agrees to be bound by terms of confidentiality and non-use comparable in scope to those set forth in this Clause 18.4;
and

 

		(d)	disclosure to third parties in connection with due diligence or similar investigations by such third parties,
and disclosure to potential third party investors in confidential financing documents, provided, in each case, that any such third party
agrees to be bound by reasonable obligations of confidentiality and non-use.

 

Notwithstanding
the foregoing, in the event the Receiving Party is required to make a disclosure of the Disclosing Party’s Confidential Information
pursuant to sub-clause (a) of this Clause 18.4.3, it will, except where impracticable, give reasonable advance notice to the Disclosing
Party of such disclosure and use efforts to secure confidential treatment of such information at least as diligent as the Receiving Party
would use to protect its own confidential information, but in no event less than reasonable efforts.

 

    Page 29 of 34

    

    

 

		18.5	Neither Party shall be liable for any failure or delay in performance of its obligations (other than payment
obligations) to the extent such delay or non-performance is caused by a Force Majeure Event. The non-performing Party shall notify the
other Party of such Force Majeure Event as soon as reasonably practicable after such occurrence by giving written notice to the other
Party stating the nature of the event, its anticipated duration, and any action being taken to avoid or minimize its effect. The suspension
of performance shall be of no greater scope and no longer duration than is necessary and the non-performing Party shall use all reasonable
efforts to remedy its inability to perform.

 

		18.6	If any term of this Agreement is found by any court of competent jurisdiction to be illegal, invalid,
void or unenforceable such term shall be deemed to be severed from this Agreement and this will not affect the remainder of this Agreement
which shall continue in full force and effect. In this event the Parties will seek to agree a valid and enforceable term to replace the
severed term which to the maximum extent possible achieves the Parties’ original commercial intention.

 

		18.7	This Agreement and the licenses and other rights conferred upon each Party under this Agreement are personal
and cannot be transferred, sublicensed, assigned or otherwise disposed of by that Party without the prior written consent of the other
Party, which consent the other Party may withhold in its sole and absolute discretion, except that either Party may assign this Agreement
and its rights and obligations hereunder without the other Party’s consent either:

 

		18.7.1	in connection with the transfer or sale of all or substantially all of such Party’s business to
a third party, whether by merger, sale of stock, sale of assets or otherwise (each, a ’Sale Transaction’); provided,
however, that in the event of a Sale Transaction (whether this Agreement is actually assigned or is assumed by the acquiring third
party by operation of law (e.g., in the context of a reverse triangular merger)):

 

		(a)	intellectual property rights of the acquiring third party that existed prior to the Sale Transaction shall
not be included in the technology licensed hereunder or otherwise subject to this Agreement;

 

		(b)	products of the acquiring third party that existed prior to the Sale Transaction and products that are
developed (other than by modification of products owned by or licensed to such Party prior to the Sale Transaction) or acquired by the
acquiring third party after the Sale Transaction shall not be subject to Section 17; and

 

		(c)	in the case of a Sale Transaction with respect to Distributor in which the acquiring third party is, as
of the time of such Sale Transaction, engaged in the commercialisation of any Competing Product in the Territory, Company shall have the
one-time right to terminate this Agreement, exercisable by written notice delivered to Distributor no later than thirty (30) days after
the earlier of (i) delivery by Distributor to Company of written notice of the consummation of such Sale Transaction and (ii) the first
public announcement of the consummation of such Sale Transaction. For clarity, the termination right set forth in this sub-clause 18.7.1(c)
is in addition to Company’s rights of termination under Section 14; or

 

    Page 30 of 34

    

    

 

		18.7.2	to an Affiliate of such Party, provided that the assigning Party shall remain liable and responsible to
the non-assigning Party hereto for the performance and observance of all such duties and obligations by such Affiliate.

 

The rights and obligations
of the Parties under this Agreement shall be binding upon and inure to the benefit of the successors and permitted assigns of the Parties,
and the name of a Party appearing herein will be deemed to include the name of such Party’s successors and permitted assigns to
the extent necessary to carry out the intent of this section. Any assignment not in accordance with this Agreement shall be void.

 

		18.8	A waiver of any right or remedy under this Agreement or by law is only effective if given in writing and
shall not be deemed a waiver of any subsequent breach or default. A failure or delay by a Party to exercise any right or remedy provided
under this Agreement or by law shall not constitute a waiver of that or any other right or remedy, nor shall it prevent or restrict any
further exercise of that or any other right or remedy. No single or partial exercise of any right or remedy provided under this Agreement
or by law shall prevent or restrict the further exercise of that or any other right or remedy.

 

		18.9	Any formal notice required to be given by either Party in this Agreement shall be in writing and in English
and sent to the other Party at its address set forth above (or at such other address as shall have been designated by such other Party
in writing). Notices may be given and shall be deemed received:

 

		18.9.1	by first-class post: two Business Days after posting;

 

		18.9.2	by airmail: seven Business Days after posting; or

 

		18.9.3	by hand: on delivery.

 

		18.10	This Agreement and the documents referred to herein constitute the entire agreement between the Parties
with respect to its subject matter, supersede all previous agreements or understandings with respect thereto and may not be modified except
by an instrument in writing signed by the duly authorised representatives of the Parties. Each Party acknowledges that is not entering
into this Agreement in reliance upon and shall have no remedy in respect of any representation or warranty not set out in this Agreement.
Nothing in this clause excludes liability for fraud or fraudulent misrepresentation.

 

		18.11	Any amendments of this Agreement shall not be binding on the Parties unless set out in writing, expressed
to amend this Agreement and signed by authorised representatives of each of the Parties.

 

		18.12	The Contracts (Rights of Third Parties) Act 1999 shall not apply to this Agreement and no person other
than the parties to this Agreement shall have any rights under it.

 

		18.13	This Agreement is to be interpreted in accordance with the following:

 

		18.13.1	Clause, Schedule and paragraph headings shall not affect the interpretation of this Agreement;

 

		18.13.2	a person includes a natural person, corporate or unincorporated body (whether or not having separate legal
personality) and that person’s personal representatives, successors and permitted assigns;

 

    Page 31 of 34

    

    

 

		18.13.3	the Schedules form part of this Agreement and shall have effect as if set out in full in the body of this
Agreement. Any reference to this Agreement includes the Schedules;

 

		18.13.4	a reference to a company shall include any company, corporation or other body corporate, wherever and
however incorporated or established;

 

		18.13.5	a reference to a statute or statutory provision is a reference to it as amended, extended or re-enacted
from time to time;

 

		18.13.6	references to Clauses and Schedules are to the Clauses and Schedules of this Agreement and references
to paragraphs are to paragraphs of the relevant Schedule; and

 

		18.13.7	any words following the terms ‘including’, ‘include’, ‘in particular’,
‘for example’ or any similar expression shall be construed as illustrative and shall not limit the sense of the words, description,
definition, phrase or term preceding those terms.

 

		18.14	Distributor acknowledges that Company may have no adequate remedy under this Agreement or at law in the
event that Distributor were to use the Intellectual Property Rights in a manner not authorised by this Agreement, and each Party acknowledges
that the other Party may have no adequate remedy under this Agreement or at law in the event of such Party’s breach of Clause 18.4,
and that, in each case, the non-breaching Party would, in such circumstances, be entitled to seek specific performance, injunctive or
other equitable relief, including interlocutory and preliminary injunctive relief.

 

		18.15	Each Party’s rights and remedies under this Agreement and under the law are intended to be cumulative,
and not mutually exclusive.

 

		18.16	This Agreement shall be governed by and construed in accordance with English law.

 

		18.17	Subject to Clause 4.8, the Parties irrevocably agree that the federal courts located in the State of New
York, USA, shall have exclusive jurisdiction to settle any dispute or claim that arises out of or in connection with this Agreement, and
the Parties hereby submit and consent to the exclusive jurisdiction of the federal courts located in the State of New York, USA.

 

Data Privacy

 

		18.18	Each Party acknowledges that, for the purposes of the Data Protection Laws, it is a controller in relation
to the Shared Data and that it independently determines the purposes for which and the manner in which any Shared Data is processed.

 

		18.19	Each Party shall:

 

		18.19.1	comply with its obligations under Data Protection Laws;

 

		18.19.2	to the extent permitted by Data Protection Laws, deal promptly and in good faith with all reasonable and
relevant enquiries from the other Party relating to its processing of the Shared Data; and

 

		18.19.3	assist the other Party to enable that Party to comply with its obligations under Data Protection Laws.

 

    Page 32 of 34

    

    

 

		18.20	Without limiting Clause 18.19, each Party warrants, represents and undertakes to the other that:

 

		18.20.1	it collected the Shared Data in accordance with Data Protection Laws; and

 

		18.20.2	it has the right to disclose the Shared Data to the other Party.

 

Announcements

 

		18.21	Save as provided in the sub-clauses below, neither Party shall make or authorise any public announcement
or communication concerning this Agreement except:

 

		18.21.1	to the Parties’ auditors, insurers and legal professional advisers (and solely on a confidential basis);

 

		18.21.2	to the Parties’ Affiliates on a confidential and strictly need to know basis only;

 

		18.21.3	where either Party is under a legal or regulatory obligation to make such disclosure, but limited to the extent of that legal or regulatory
obligation;

 

		18.21.4	to the extent that the information is already in the public domain other than through breach of this clause;

 

		18.21.5	to the extent necessary to implement and enforce any terms of this Agreement;

 

		18.21.6	to the extent required by Applicable Laws or the listing requirements of any exchange on which a Party’s or its Affiliate’s
securities are listed; or

 

		18.21.7	with the prior written consent of the other Party (such consent not to be unreasonably withheld).

 

		18.22	If any exception in the sub-clauses above applies, the Party permitted to make the disclosure shall promptly
notify the other Party prior to that disclosure and shall, to the extent permitted by law, use reasonable endeavours to obtain from the
relevant third party an agreement to maintain confidentiality on the same terms as the Agreement of the Parties in this clause.

 

[Signature page follows]

 

    Page 33 of 34

    

    

 

In Witness Whereof, the
Parties have, by duly authorized persons, executed this Agreement as of the Effective Date.

 

	Sinclair Pharma US Inc.	 	Suneva Medical, Inc.
	 	 	 
	By:	 	 	By:	 
	 	 	 
	Name: 	 	 	Name: 	 
	 	 	 
	Title:	 	 	Title:	 

 

 

Page 34 of 34

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00346-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00346-of-00352.parquet"}]]